Risperidone for disruptive behaviour in children and adolescents with learning disability by Bezuidenhout, Heidre
  
RISPERIDONE FOR DISRUPTIVE BEHAVIOUR IN 
CHILDREN AND ADOLESCENTS WITH LEARNING DISABILITY 
 
 
 
Dr Heidré Bezuidenhout 
WITS Student no. 0516563w 
 
 
  
 
 
 
 
  
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree 
of Master of Science in Medicine (Child Health Neurodevelopment).  
  
Cape Town, September 2009  
 i
DECLARATION  
 
I, HEIDRE BEZUIDENHOUT declare that this research report is my own work. It is 
submitted for the degree of Master of Science in Medicine (Child Health 
Neurodevelopment) at the University of the Witwatersrand, Johannesburg. It has not 
been submitted before for any degree or examination at this or any other University.  
  
  
  
  
  
SIGNED: ____________________________  
  
  
DATE:   13
th
 September 2009  
  
 ii
NOTE ABOUT COCHRANE SYSTEMATIC REVIEW FORMAT  
 
The research contained in this thesis has been registered as a systematic review of the 
same title with the Cochrane Collaboration, Developmental Psychosocial and 
Learning Problems Group.  The structure and format of this thesis therefore follows 
the strict guidelines of the Cochrane Collaboration.  
 iii
ABSTRACT  
 
Background  
Disruptive behaviour is the most commonly reported mental health problem in 
individuals with learning disability. Pharmacotherapy is part of a multidisciplinary 
approach to the treatment of disruptive behaviour. Risperidone, an atypical 
antipsychotic drug, is the most commonly used treatment for symptom improvement. 
It is therefore important to establish the efficacy and safety of risperidone therapy in 
this dependent, vulnerable and young population, given the well documented adverse 
effects and the potential for long term treatment. 
 
Objectives  
To assess the effects of risperidone for disruptive behaviour in children and 
adolescents with learning disability. 
 
Search strategy  
The following electronic databases were searched: CENTRAL (Cochrane Central 
Register of Controlled Trials); MEDLINE; PsycINFO; CINAHL; Clinicaltrials.gov; 
National Research Register (NRR). In addition, reference lists of relevant publications 
and narrative reviews were checked; handsearches were done; authors of published 
trials and pharmaceutical manufacturer of risperidone (Risperdal) were contacted. 
 
Selection criteria  
All randomised or quasi-randomised controlled trials of risperidone versus placebo (or 
no treatment) for children and adolescents (age less than 18 years) with a diagnosis of 
learning disability and disruptive behaviour were considered.  
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Data collection and analysis  
Trial eligibility and data quality were evaluated and analysed by the author and 
independently verified by an additional reviewer. Unpublished data were considered 
for inclusion and relevant authors were contacted in the case of incomplete data. 
 
Results  
Four randomised controlled trials involving 279 children and adolescents were 
identified. The majority of the children were living at home and not institutionalised. 
Meta-analyses of the primary outcome scales (Nisonger Child Behaviour Rating 
Form, Aberrant Behaviour Checklist, Behaviour Problem Inventory) measuring 
several core symptoms of disruptive behaviour, namely conduct problems, self-injury, 
irritability, aggressive / destructive behaviours and stereotypy suggest statistically 
significant improvement in disruptive type behaviours in children treated with 
risperidone compared to placebo. Adverse event data showed that the prevalence of 
adverse effects viz. weight gain, sedation / somnolence and raised prolactin levels 
were significantly higher in the children receiving risperidone. 
 
Conclusions  
In the studies included in this review, risperidone treatment for disruptive behaviour 
in learning disabled children and adolescents appears to have a beneficial effect on 
certain symptoms of disruptive behaviour. However, the applicability of these 
findings to wider clinical practice remains unclear, due to poor methodological 
quality, inadequate study sample size and short duration of treatment of the included 
studies. Long term safety has not been established and serious adverse effects, 
affecting growth, are of concern. Further research is required to establish the efficacy 
and safety of risperidone for disruptive behaviour in learning disabled children and 
adolescents in clinical practice.  
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PLAIN LANGUAGE SUMMARY  
 
Risperidone is a medication, usually used for the treatment of psychotic disorders in 
adults, which has also been used to treat disruptive behavioural problems, such as 
aggression, in people with learning disability (below normal intellect). This review 
showed that four studies found risperidone beneficial for improving certain symptoms 
of disruptive behaviour, however, the studies were small and had some technical 
issues that could affect their validity and applicability. In addition, potentially harmful 
side effects affecting growth, were identified. Further research is necessary to 
determine if the benefits of risperidone outweigh the potential risks. 
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1. BACKGROUND  
1.1. DESCRIPTION OF THE CONDITION  
 
1.1.1. Learning Disability 
Terminology 
The definition and classification of individuals with impairment of intellectual 
functioning is the subject of an ongoing global debate in the field of mental health. 
Various terms and criteria are used in different countries throughout the world, 
leading to confusion and complexity in both clinical and academic settings. The term 
"learning disability" in this review is consistent with the definition used in the United 
Kingdom which refers to individuals with a lower than normal intellectual 
functioning. In the United States of America (USA) and Canada, the term "learning 
disability" refers to individuals with specific problems with learning academic skills, 
for example impairments of speaking, listening, reading, writing, spelling and doing 
mathematics. In the USA and Canada, impaired intellectual functioning is referred to 
as "intellectual disability" or '"mental retardation". 
 
There is no global consensus on the terminology referring to individuals with 
impaired intellectual functioning, however there is a move towards removing the 
stigma of the labels these individuals have been given in the past - terms like 
imbecile, cretin and moron have fallen out of favour. The latest development in the 
USA is to change the current term "mental retardation" to "intellectual disability". The 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (APA 1994) and 
the International Classification of Diseases (ICD-10) (WHO 1992) still refer to this 
condition as "mental retardation", but this is likely to change in future editions as the 
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American Association on Mental Retardation (AAMR) have formally changed their 
name  to the American Association on Intellectual and Developmental Disabilities 
(AAIDD). 
 
Definition 
The definition of learning disability comprises the impairment of both cognitive and 
adaptive functioning, with onset during the first 18 years of life, during childhood or 
adolescence (APA 2000; WHO 1992).  
 
Cognitive functioning is normally measured by the Intelligence Quotient (IQ) using 
standardised psychometric tests, which are valid and reliable for the individual's 
circumstances (sensitive to culture, language or other disabilities).  
 
Adaptive functioning refers to an individual's ability to function well on a personal 
and social level in different circumstances, adapting and adopting specific behaviours 
to suit the different settings of daily life (work, play and home). The child's social 
environment demands certain behaviours that display social maturity. These 
behaviours change as a child matures into adulthood and accomplishes social 
maturity. Adaptive skills are dependant on the community and culture the individual 
grows up and lives in. Instruments to measure adaptive functioning are often in the 
form of questionnaires or interviews with the carers of the individual to assess 
everyday performance. Individuals with learning disability may have the ability to 
display certain behaviour, but do not routinely display such behaviour when the 
setting requires it. Impaired adaptive functioning is often the most notable presenting 
feature of an individual with learning disability and is also the area in which the most 
improvement is seen with remedial therapy. 
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Synonyms for learning disability in medical literature are "mental retardation", 
"intellectual disability", "subaverage intelligence", "subnormal intelligence", 
"cognitive disability", "mental handicap" and "oligophrenia". 
 
Aetiology 
There are multiple aetiologies of learning disability: genetic disorders, congenital 
malformations, metabolic, ante- and perinatal causes such as infection and toxin 
exposure, birth asphyxia, postnatal infections, trauma, nutritional, metabolic and 
psychosocial problems. In 30-50% of cases the aetiology is unknown despite intensive 
investigation (Sadock 2005). The more severe forms of learning disability are more 
likely to have an identifiable organic cause. Learning disabilities are 1.5 times more 
common amongst males than females (APA 2000) and individuals with learning 
disability have a greater risk to have a concomitant mental illness. Neurological 
conditions, for example seizures and behavioural problems, are also more prevalent in 
this population (APA 2000). 
 
Prevalence 
The prevalence of learning disability in the USA is estimated at approximately 1% of 
the general population (APA 2000), and approximately 2% in the United Kingdom 
(Emerson 2004). South African data is sparse, however the "CASE Disability survey" 
for the Department of Health undertaken in 1997, estimated the prevalence of learning 
disability in South Africa to be 1.1% (CASE 2002). A later study showed the 
prevalence to be as high as 35.6 per 1000 (3.56%) in rural settings (Christianson 
2002). 
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Classifications 
The classifications most frequently used in clinical practice and research to diagnose 
an individual with learning disability are the DSM IV-TR (the latest 2000 text 
revision of the 1994 publication) (APA 2000) and the ICD-10 (WHO 1992); both of 
these classifications use the term "mental retardation" when referring to "learning 
disability". 
 
DSM IV-TR: Mental Retardation 
The DSM IV-TR classification consists of 5 Axes on which diagnoses could be made. 
Mental retardation is an Axis II diagnosis, code 317. Table 1 presents the criteria to 
diagnose mental retardation using the DSM IV-TR classification. The diagnosis of 
mental retardation is further refined as levels of impaired intellectual functioning, as 
displayed in Table 2. 
 
Table 1.  DSM IV-TR Criteria to diagnose Mental Retardation 
A. Significantly subaverage intellectual functioning: an IQ of approximately 70 or 
below on an individually administered intelligence test (for infants, a clinical 
judgement of significantly subaverage intellectual functioning). 
B. Concurrent deficits or impairments in adaptive functioning (i.e. the person's 
effectiveness in meeting the standards expected for his or her age by his or her 
cultural group) in at least two of the following skill areas: communication, self-care, 
home living, social or interpersonal skills, use of community resources, self-direction, 
functional academic skills, work, leisure, health, and safety. 
C. Onset before 18 years of age. 
Table from:American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders:DSM IV. 
4th edition. Text revision. Washington, DC: American Psychiatric Association, 2000. 
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Table 2.  DSM IV-TR Levels of Mental Retardation 
Mild mental retardation (IQ of 55 to 70) 
Individuals with mild mental retardation are usually only identified on entering formal 
schooling; may achieve sixth grade academic skills or some may even graduate from 
high school; able to acquire some vocational skills; usually able to live independently 
and self-support as adults, but may need support and guidance when stressed. 
Moderate mental retardation (IQ 40 to 55) 
Individuals with moderate mental retardation are usually identified before entering 
school; most will need special education services; at school most will progress to 
second or third grade level; able to acquire some basic vocational skills and perform 
unskilled or semi-skilled work under sheltered conditions; most will require 
supportive services throughout their lifetime. 
Severe mental retardation (IQ of 25 to 40) 
Individuals with severe mental retardation often have an identifiable organic cause to 
explain their developmental delays, that often includes motor and other neurological 
dysfunction as well; most will not benefit from education services except in pre-
academic subjects, but may be taught some simple routines; most not able to acquire 
even basic vocational skills; most will require specialized supportive services 
throughout their lifetime. 
Profound mental retardation (IQ of 25 and below) 
Individuals with profound mental retardation often have an identifiable organic cause 
to explain their early and prominent developmental delays across all areas (motor, 
communication, cognitive); most will require nursing care and constant supervision 
throughout their lifetime, many will even need intensive training to attend to basic 
self-care routines like eating and toilet-habits. 
Borderline intellectual functioning usually refers to individuals with an IQ range of 71 
to 84. But as there is a measurement error of 5 points on an IQ score, some clinicians 
or researchers may diagnose mental retardation in an individual with an IQ score 
above 70, if they have impairment of adaptive functioning. 
Table from: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM IV. 
4th edition. Text revision. Washington, DC: American Psychiatric Association, 2000. 
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ICD-10: Mental retardation 
The ICD-10 definition of mental retardation is presented in Table 3. The classification 
includes levels of severity as well as levels of associated behavioural impairments, as 
presented in Table 4. 
 
Table 3.  ICD-10 Definition of Mental Retardation  
A condition of arrested or incomplete development of the mind, which is especially 
characterized by impairment of skills manifested during the developmental period, 
which contribute to the overall level of intelligence, i.e. cognitive and language, motor 
and social abilities. Adaptive behaviour is always impaired, but in a protected social 
environment where support is available this impairment may not be at all obvious in 
subjects with mild mental retardation. Reduced level of intellectual functioning 
resulting in diminished ability to adapt to the daily demands of the normal social 
environment. 
From: World Health Organization. International Classification of Disease and related disorders (ICD-10). 
Geneva: World Health Organisation, 1992. 
 
Table 4.  ICD-10 Levels of Mental Retardation 
ICD-10 Levels of Mental Retardation 
F70 Mild mental retardation (IQ of 50 to 69) 
F71 Moderate mental retardation (IQ of 35 to 49) 
F72 Severe mental retardation (IQ of 20 to 34) 
F73 Profound mental retardation (IQ of less than 20) 
F78 Other mental retardation - Sensory, physical and behavioural impairments 
preclude IQ testing 
F79 Unspecified mental retardation - Evidence of mental retardation, but insufficient 
information is available to assign the individual to categories F70-F78. 
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ICD-10 Code to specify concurrent behavioural impairment
F7x.0 No, or minimal, impairment of behaviour 
F7x.1 Significant impairment of behaviour requiring attention or treatment 
F7x.8 Other impairments of behaviour 
F7x.9 Without mention of impairment of behaviour 
From: World Health Organization. International Classification of Disease and related disorders (ICD-10). 
Geneva: World Health Organisation, 1992. 
 
1.1.2. Disruptive Behaviour 
Definition and classification 
For the purposes of this review, the term "disruptive behaviour" is used to describe 
the following: 
- persistent patterns of socially unacceptable behaviour that is either aggressive 
behaviour towards others and/or self; 
- stereotypic, repetitive self-harm behaviours; or 
- violent and destructive actions and defiance. 
 
Disruptive behaviour corresponds to the term "challenging behaviour" that is more 
often used in adult research literature and publications to describe the aforementioned 
patterns of behaviours (Emerson 1995). Classification systems like the DSM IV-TR 
and ICD-10 do have formal codes to describe disruptive type disorders (Tables 5 and 
6 respectively), although studies describing disruptive behaviour in children seldom 
use them. Disruptive behaviours in the DSM IV-TR classification system are 
categorised as either oppositional defiant disorders or conduct disorders (APA 2000). 
The previous edition, the DSM IV, included a category - Disruptive behaviour 
disorders not otherwise specified (NOS) - which has been used in some publications 
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(APA 1994). Disruptive behaviours in the ICD-10 classification system are 
categorised as either conduct disorder confined to the family context, oppositional 
defiant disorders, other conduct disorders, conduct disorder, unspecified, conduct or 
oppositional defiant disorders. 
 
Aetiology and prevalence  
Disruptive behaviour is the most common psychiatric diagnosis in children with a 
prevalence of 4-9% (Scott 1998). There are currently no specific known causes and it 
is unclear whether disruptive behaviour is in fact a mental illness with a biological 
basis, or a symptom complex resulting from an interplay between the environment, 
biology and psychology of an individual, emerging during development. The latter 
seems the most plausible explanation. There is a higher incidence of disruptive 
behaviour in males and those with a family history, suggesting a genetic component 
(Sadock 2005). There is some evidence to suggest that disruptive types of behaviour 
may be a serotonergic effect, and that is why the serotonin-antagonistic type drugs 
may  improve such symptoms (Eichelman 1992). 
 
The population of children with learning disability has a high prevalence of disruptive 
behaviour disorders, contributing to the challenges these children’s caregivers have to 
contend with (Benson 1999; Campbell 1991; Scott 1998). Children with learning 
disability potentially have three to four times the risk of developing behavioural 
problems compared to other children. (Campbell 1991). Some syndromes associated 
with learning disability have well defined aggressive behavioural phenotypes, such as 
self-biting in Lesch-Nyhan syndrome and nail pulling and head banging in Smith-
Magenis syndrome. 
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Table 5.  DSM IV-TR - Disruptive Behaviour Disorders  
312. Oppositional defiant disorders 
Individual displays a persistent pattern of negativistic, hostile, disobedient and defiant 
behaviour and results in significant impairment of functioning. Usually the behaviour 
does not violate the rights of others or any social norms. Behaviour pattern has to be 
present for more than 6 months. 
312. Conduct Disorders 
Individual displays a persistent pattern of behaviour that violates the basic rights of 
others or major age-appropriate societal norms. 
From: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders:DSM IV. 4th 
edition. Text revision. Washington, DC: American Psychiatric Association, 2000. 
 
Table 6.  ICD 10 - Conduct Disorders  
The ICD-10 defines conduct disorders as: "repetitive and persistent pattern of 
dissocial, aggressive or defiant conduct. Such behaviour, when at its most extreme for 
the individual, should amount to major violations of age-appropriate social 
expectations, and is therefore more severe than ordinary childish mischief or 
adolescent rebelliousness". The pattern of behaviour must be enduring and could be 
symptomatic of other psychiatric conditions. 
F 91.0 Conduct disorder confined to the family context 
F 91.3 Oppositional defiant disorders 
F 91.8 Other conduct disorders 
F 91.9 Conduct disorder, unspecified 
From: World Health Organization. International Classification of Disease and related disorders (ICD-10). 
Geneva: World Health Organisation, 1992. 
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1.2. DESCRIPTION OF THE INTERVENTION  
 
1.2.1. Atypical Antipsychotics 
Atypical antipsychotics or second-generation antipsychotics refer to a group of 
serotonin-dopamine antagonistic drugs. They have comparable efficacy and an 
improved side-effect profile compared to first-generation antipsychotics, which work 
as dopamine receptor antagonist. This has led to a much wider use of these drugs in 
psychiatry, beyond treating schizophrenia, than the first-generation antipsychotics. 
The improved side-effect profile could be explained by the atypical antipsychotics 
blocking more serotonin type 2 receptors compared to dopamine type 2 (D2) 
receptors, and by having greater affinity for the mesolimbic system compared to the 
striatal dopamine system (Sadock 2005). The serious adverse effects of the first 
generation antipsychotics, i.e. extrapyramidal symptoms, especially tardive dyskinesia 
(a potentially irreversible neurological syndrome characterised by involuntary, 
repetitive, purposeless movements), dystonia, involuntary movements; and 
neuroleptic malignant syndrome (a symptom complex consisting of hyperthermia, 
muscle rigidity, altered mental status and instability of the autonomic system and 
carries a mortality risk) has led to the less frequent use of these agents. 
 
1.2.2. Risperidone preparations and pharmacodynamics 
Risperidone is an atypical antipsychotic initially patented and marketed as Risperdal 
by Janssen-Silag, now called Ortho-McNeil-Janssen Pharmaceuticals Inc., a 
subsidiary of Johnson & Johnson. Preparations include tablet formulation (0.5 mg, 
1mg, 2 mg, 3 mg, 4 mg), orodispersible tablets, Quicklet (0.5 mg, 1 mg, 2 mg, 3 mg,  
4 mg), oral solution (1 mg/ml) and long-acting injectable formulation (Risperdal 
Consta) (25 mg, 37.5 mg, 50 mg) (SAMF 2008) . 
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Risperidone is a benzisoxizole derivative (Figure 1) that is metabolized in the liver to 
9-hydroxy risperidone, which has the same pharmacological action as the parent 
compound. Peak plasma levels are reached within 1-2 hours of ingestion. The 
mechanism of action is via central serotonin (especially 5-HT2A ) and dopamine (D2) 
receptor antagonism. Risperidone also has high affinity for α1 and α2 -receptors and 
lower affinity for β-adrenergic and muscarinic receptors.  
 
Ortho-McNeil-Janssen’s patent for risperidone expired in December 2007 and the 
Food and Drug Administration (FDA) approved a generic version of risperidone in 
July 2008, manufactured by TEVA pharmaceuticals. Currently a generic version of 
risperidone is available and manufactured by several other pharmaceutical companies 
(TEVA Pharmaceuticals, Apotex Corporation, Mylan Pharmaceuticals, Patriot 
Pharmaceuticals) in tablet and oral solution, but not in an injectable formulation. 
 
Figure 1.  Molecular structure of risperidone  
 
1.2.3. Indications for use 
The South African Medicines Formulary 2008 (SAMF) states the indications for 
risperidone as: Adults - Schizophrenia, acute or chronic psychoses. Behavioural 
symptoms (aggression, wandering, agitation) and psychosis associated with dementia. 
Paediatrics - Disruptive behaviour disorders in children older than 5 years with sub-
average intellectual functioning or mental retardation. Contraindicated in children 
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under 5 years. Efficacy and safety not established in schizophrenia in children under 
15 years old. Paediatric dose: Oral, 5-12 years under 50 kg, initially 0.01 mg/kg once 
daily, increased if necessary by 0.01 mg/kg/day not more frequently than every other 
day. Maintenance 0.02-0.04 mg/kg daily (SAMF 2008). 
 
In the United States risperidone was approved in October 2006 by the Food and Drug 
Administration (FDA) for treatment of irritability in autistic children (5 -16 years) 
(FDA 2006) and in August 2007 approved for treatment of schizophrenia in children 
(age 13 to 17) as well as treatment of bipolar disorder in children age 10 to 17 years 
(FDA 2007). Risperidone is not currently registered in the United States to be used to 
treat disruptive behaviour in children and adolescents with learning disability/ mental 
retardation, but is used off-label in practice regardless (FDA 2009). 
 
1.2.4. Adverse effects 
The South African Medicines Formulary 2008 (SAMF) lists the adverse effects of 
risperidone as: Common - insomnia, agitation, extrapyramidal effects, anxiety, 
headache, sedation (more frequent in children/ adolescents than adults). Uncommon - 
somnolence, fatigue, dizziness, impaired concentration, constipation, dyspepsia, 
nausea, vomiting, abdominal pain, weight gain, blurred vision, priaprism, erectile 
dysfunction, urinary incontinence, rhinitis, rash and other allergic reactions. Tardive 
dyskinesia, seizures, orthostatic hypotension, cerebrovascular events, 
hyperprolactinaemia (galactorrhoea, gynaecomastia, menstrual disturbances), 
hyponatraemia due to polydipsia or syndrome of inappropriate anti-diuretic hormone 
(SIADH), and temperature dysregulation have been reported. Rare complications 
include neuroleptic malignant syndrome, hyperglycaemia following intramuscular 
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injection, and in some extreme cases keto-acidosis or hyperosmolar coma or death 
(SAMF 2008). 
 
A boxed warning has been issued by the manufacturers of risperidone for its use in 
the treatment in the elderly patient with dementia-related psychosis after trials showed  
an increased mortality  in this population group. Risperidone is currently not approved 
to be used for the treatment of individuals with dementia-related psychosis in the 
United States (FDA 2009). 
 
 Weight gain and its resulting metabolic sequelae (insulin insensitivity or diabetes 
mellitus, hyperlipidaemia) is a commonly reported adverse event of risperidone use, 
possibly explained by the H1 and 5-HT2c receptor blockage. Raised plasma prolactin 
levels may be a consequence of dopamine (D2) receptor activity. 
 
1.3. HOW THE INTERVENTION MIGHT WORK  
1.3.1. Management of Disruptive Behaviour in Individuals with Learning Disability 
Disruptive type behaviour or "aggressive, antisocial and self-injurious behaviour" 
(Aman 1991) is the most commonly reported mental health problem in individuals 
with learning disability. A multidisciplinary approach to the treatment of disruptive 
behaviours includes cognitive therapy, behaviour treatment, psychotherapy, social 
learning therapy, enhancement of parental skills and pharmacotherapy. The cognitive 
and behavioural modification therapies are an essential part of the holistic 
management plan for an individual with learning disability, though quite costly and 
labour intensive, with a long latency before any positive effects may be observed. 
Individuals with a severe level of learning disability may also have limited benefit 
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from cognitive therapies. A Cochrane review done on the efficacy of behavioural and 
cognitive-behavioural interventions for aggressive behaviour in learning disabled 
people found little evidence to support the efficacy of these interventions (Hassiotis 
2004). Pharmacotherapy for disruptive behaviour is often used in conjunction with the 
other treatment modalities. The first antipsychotic agent to be used to treat 
behavioural problems was chlorpromazine in the 1950’s (Schaal 1994). The 
introduction of the newer atypical antipsychotic agents has sparked a renewed interest 
in the use of antipsychotics for the pharmacotherapy of behavioural problems, 
especially in children, as these agents have fewer reported adverse effects. 
Risperidone, in particular, has been the agent used in numerous studies to establish 
the pharmacological efficacy in improving disruptive types of behaviour. 
 
1.3.2. Literature reviews 
A number of published randomised controlled studies and reviews have assessed 
antipsychotics, in particular risperidone, for symptoms of aggression and irritability 
both in adults and children. These publications are presented below as an overview of 
relevant evidence in the field, with a more detailed discussion of the publications 
concerning risperidone use in children with learning disability in section 4 of this 
review. 
 
Normal or near normal intelligence 
A small randomised controlled study found that risperidone use in children with 
normal intelligence and a diagnosis of conduct disorder resulted in an improvement of 
aggression symptoms and was not associated with extra-pyramidal side-effects 
(Findling 2000). Nevertheless the authors did stress that the findings of this pilot 
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study should not be applied to all children with conduct disorders. A large 
randomised, placebo-controlled  study on risperidone maintenance for disruptive 
behaviour disorders in children and adolescents with a wide range of intellectual 
disability (IQ > 84) concluded that risperidone was of benefit  in children who 
initially responded to the drug and then prescribed  for an additional 6 months (Reyes 
2006b). Risperidone at low-doses improved a wide range of behavioural and social 
symptoms in children enrolled in the study. 
 
Learning disability 
Several  published randomised controlled studies assessing the use of risperidone in 
children with learning disability, found risperidone to be well tolerated and effective 
in treating  severely disruptive behaviours (such as aggression and destructiveness) 
(Aman 2002, Buitelaar 2001, Snyder 2002). Risperidone was also found to be 
significantly more effective than placebo in controlling behavioural disturbances (Van 
Bellinghen 2001). Cross-over studies that included both children and adults with 
learning disability showed risperidone to be effective in treating behavioural 
disturbances (Hellings 2006; Vanden 1993; Zarcone 2001). Hellings et al observed 
risperidone to have significant adverse effects in the form of increased appetite, 
weight gain and sedation. A recent randomised controlled study undertaken in adults 
with learning disability assessing risperidone, haloperidol and placebo concluded that 
the use of antipsychotics to treat behavioural problems in learning disabled 
individuals should not be recommended as a first line treatment, even at low doses, as 
treatment with risperidone or haloperidol were not found to be superior to placebo 
(Tyrer 2008). The authors supported alternative forms of management i.e. 
psychological interventions. 
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Predominantly positive reviews 
A literature review done on the use of antipsychotics in individuals with intellectual 
disability by La Malfa concluded that risperidone was the most efficacious and safest 
drug to use in this population group for behavioural problems. However, the review 
authors did comment extensively on the inadequate methodological quality of the 
majority of the included studies (La Malfa 2006). The review referred to two 
consensus conferences that promoted the efficacy and safety of atypical 
antipsychotics to treat behavioural problems in learning disability (AAMR 2000; 
SIRM 2002).  
 
A literature review done by Dr G Pandina, Director of Clinical Development at 
Janssen Pharmaceutica Inc., on risperidone for disruptive behaviour in paediatric 
patients concluded that there was enough evidence to show the efficacy of risperidone 
to treat  disruptive behaviour disorders in children (Pandina 2006). A recommendation 
arising from the review was the need to anticipate possible adverse effects resulting 
from the use of risperidone such as excessive weight gain, premature sexual 
maturation and metabolic derangements. 
 
 Another review that recommended the use of psychotropic medication such as 
risperidone, for behavioural problems in learning disability also highlighted the 
possible adverse effects of the drug (Deb 2007). The reviewers were concerned about 
the poor methodological quality of the current literature on this topic and emphasized 
the need for further research in this area.  
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Predominantly negative reviews 
A recent review of evidence-based treatments for individuals with learning disability 
concluded that current evidence does not support the use of risperidone for the 
management of behavioural problems in patients with learning disorders (Ulzen 
2008). The review commented on the small sample sizes, poor methodological 
quality, the lack of emphasis on important issues such as polypharmacy, and the use 
of depot preparations. The reviewers proposed that future literature include important 
issues such as management of acute onset agitation and the prevalence of underlying 
organic aetiology as cause for disruptive behaviour.  
 
A systematic review by South African authors reviewing pharmacotherapy of 
disruptive behaviour disorders in children and adolescents highlighted the fact that 
there are currently no registered medications to treat disruptive behaviour disorders 
(Ipser 2007). They concluded that the results of two randomised controlled trials 
(Aman 2002; Snyder 2002) showing significant benefit for risperidone, should be 
interpreted with caution as many of the study participants were receiving psychotropic 
medication at the same time. The reviewers concluded that there was not sufficient 
evidence at the time to advocate the use of risperidone to treat disruptive behaviour in 
children, and that further research was needed to further explore the high prevalence 
of adverse events and establish its long term safety. This review did not explore 
disruptive behaviour in children or adolescents with learning disability. 
 
A review done by Singh et al on the use of risperidone among learning disabled 
individuals found that its general use was not evidence-based (Singh 2005). These 
authors also commented on the poor methodological quality of studies reported in the 
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current literature and suggested recommendations for improving the design for future 
studies.  
 
Another comprehensive review done by Matson et al on psychopharmacology in 
patients with learning disability found no evidence to support the use of 
antipsychotics to treat aggression in individuals with learning disability (Matson 
2000). The authors raised the important question of ethics in this vulnerable 
population and included criticism for the poor methodological quality of studies that 
have been published. In their conclusion the authors issued the following statement:  
"given the overall paucity of evidence, the continued, inappropriate use of 
psychotropic medications in persons with mental retardation extends beyond a 
question of ethics and becomes an urgent moral dilemma" (Matson 2000).  
 
A Cochrane systematic review done on the use of antipsychotic agents for disruptive 
behaviour in adults with learning disability concluded that caregivers of people with 
learning disability should be informed of the "paucity of evidence for the efficacy of 
this treatment" (Brylewski 2004). 
 
There is no published systematic review or meta-analysis on the use of risperidone for 
disruptive behaviour in children with learning disability. Most of the published 
reviews on risperidone for treatment of disruptive behaviour are focused specifically 
on adult patients.   
 
Safety  
The long term safety of risperidone therapy in children with disruptive behaviour was 
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explored by a publication containing  pooled data from 5 studies, (n=350 for growth 
data, n=222 for sexual maturation data), in children aged 5 – 15 years, treated with 
risperidone of up to 1 year. They concluded that there was no clinical or statistical 
evidence to indicate growth failure or sexual maturation failure or progression 
(Dunbar 2004). This publication did not evaluate long-term weight gain as a safety 
outcome. A few open label studies have reported on the adverse effects experienced 
by patients treated with risperidone and found somnolence, weight gain, headaches 
and raised prolactin levels to be the most common adverse effects (Croonenberghs 
2005; Findling 2004; Turgay 2002). Adverse events that lead to the discontinuation of 
a study using risperidone by  Croonenburghs et al (n=504), was weight gain in nine 
patients, increased appetite in four patients, gynaecomastia in three patients, 
somnolence in three patients, headache in three patients and extrapyramidal 
symptoms in six patients (two cases of tardive dyskinesia). Extrapyramidal adverse 
effects resulted in five patients (1%) needing additional anti-parkinsonism 
medications during the study. The incidence of important reported adverse effects in 
the study were as follows: any adverse event 462 (91.7%), somnolence 149 (29.6%), 
weight gain 87 (17.3%), and hyperprolactinaemia 56 (11.1%). 
 
Autism  
A Cochrane systematic review on the use of risperidone for autism spectrum disorders 
concluded that risperidone is beneficial in some of these patients with behavioural 
disturbances.  A small number of randomised controlled trials were suitable for 
inclusion and because the majority had small sample sizes, the author concluded that 
"carers and clinicians should be aware of the paucity of evidence in administering this 
drug in such a vulnerable group of people" (Jesner 2007). 
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WHY IT IS IMPORTANT TO DO THIS REVIEW  
The effective management of behavioural problems in children with learning 
disability is of great importance and can improve the quality of life for the learning 
disabled individual. Disruptive behaviour is also very challenging for the caregivers 
of children with learning disability who have to act in their best interest and provide a 
treatment that has proven to be safe. In an attempt to address the need and strive for 
evidence-based care, the American Journal on Intellectual and Developmental 
Disabilities are calling for papers to be included in a "Special Section on Evidence-
Based Practices for Persons with Intellectual and Developmental Disabilities" to be 
published in the journal over the next 3 years.  
 
The diagnosis of problem behaviours in learning disabled children, especially in those 
with poor communication abilities, as a specific disruptive behaviour disorder is very 
difficult, because the behaviour could also be a symptom of another organic illness or 
other psychosocial problem (Rush 2000). Their abnormal behaviour may be the only 
way of communicating their needs, and clinicians should be mindful of this when 
assessing an individual before implementing treatment. Tyrer et al emphasized the 
importance of accurately diagnosing the underlying cause of behavioural problems in 
individuals with learning disability (Tyrer 2008).  
 
Just as disruptive behaviour may be challenging to diagnose in a learning disabled 
individual, it is just as challenging to manage and treat the symptom complex. It is 
very important to manage it effectively, as the implications are serious for both the 
individual and their caregivers. Disruptive behaviour may result in institutional 
placement of children who have become unmanageable. Physical traumas to patients, 
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caregivers and others are a serious reality and have even led to litigation cases. The 
cost of caring for learning disabled individuals with severe disruptive behaviour on 
the health, education and social services can be excessive (Scott 1998). A costing 
analysis of the care of these individuals was done in the USA in 1989 and estimated to 
be $3 billion dollars for one year (Campbell 1991).  
 
Some authors have postulated that individuals with learning disability have a specific 
vulnerability to antipsychotics and are therefore more likely to develop adverse 
effects (La Malfa 2006). The use of risperidone in children may be hazardous and 
needs proper evidence-based scrutiny before recommending widespread use 
particularly because of its known adverse effect profile, such as affects on growth and 
sexual maturation parameters (weight and prolactin). 
 
 Polypharmacy and a high prevalence of prescribed antipsychotic drugs has been a 
concern in the learning disability population. As many as  22-45% of learning 
disabled people in the hospital setting and 20% in the community setting are taking 
antipsychotic medication (Branford 1994).  There have been concerns expressed in 
the literature about the dangers of using medications such as risperidone as a first line 
treatment option for disruptive behaviour and stressing the importance of re-
evaluating behaviour and attempting withdrawal of drug treatment in these patients 
(Ahmed 2000; Gainotti 2008; Tyrer 2008). Under resourced facilities have been guilty 
of using risperidone more frequently and earlier than clinically indicated (Turk 2008). 
In countries such as South Africa, which is poorly resourced and where support 
systems for patients with learning disability are underdeveloped, there may be 
pressure to over use pharmacotherapy in the management of behaviour disorders in 
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learning disabled children. The availability and affordability of the various generic 
formulations of risperidone could certainly allow and encourage the wider use of 
risperidone. 
 
All health interventions should be critically appraised to ensure safety and 
effectiveness of treatments. To confidently conclude that risperidone is an evidence-
based treatment for disruptive behaviour in children with learning disability, a 
systematic review of the literature using meta-analysis could be done. A meta-analysis 
is a statistical procedure used to assess individual studies with similar research 
hypothesis and design, in order to combine all of the studies’ results to produce an 
accurate and objective overall estimate of effect (Balair 1997; Borenstein 1999; 
Elwood 1998). This statistical procedure improves accuracy of data analysis, as 
studies are weighed according to their statistical power which is dependant on the 
sample size and research design rigour, before their contribution to the overall effect 
size is calculated. It is a transparent logical process, with which all the details of the 
data can be evaluated, from the research design and methodology to the final results 
and conclusions (Balair 1997; Elwood 1998). It enables the exploration of the 
heterogeneity of the different studies and allows for the results to be generalized to 
specific populations. A disadvantage of this procedure is that even though published 
and unpublished studies can and should be included in the analysis, in reality 
publication bias can distort the overall estimate of effect, as studies showing a positive 
effect are published more readily (Borenstein 1998). Nonetheless, a systematic review 
with meta-analysis is still the gold standard of data collation and analysis.  The 
Cochrane collaboration is an international network of health care professionals and 
epidemiologists based in the United Kingdom dedicated to organise and circulate 
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systematic reviews of health care interventions in order to promote evidence-based 
health care. The collaboration composes systematic reviews of randomised controlled 
trials, using meta-analysis to appraise current health care evidence to propose 
recommendations regarding current treatment practices and future research. 
 
A systematic approach using Cochrane methodology to assess the current available 
evidence in the use of risperidone for disruptive behaviour in learning disabled 
children and adolescents would therefore have important clinical and financial 
implications.  
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2. OBJECTIVES  
The objective of this review is to assess the effects of risperidone for disruptive 
behaviour in children and adolescents with learning disabilities. 
 
 
3. METHODS  
3.1. CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW  
 
3.1.1. Types of studies  
All randomised controlled trials and quasi-randomised trials that included at least one 
standardised measure of outcome, such as a behaviour checklist, used for both the 
intervention and the control group. 
 
3.1.2. Types of participants  
Participants under the age of 18 years who have been diagnosed with learning 
disability were considered for inclusion. The diagnosis must have been made using 
established diagnostic criteria - either the ICD-10 or DSM IV / IV-TR classifications. 
No restrictions were made on the setting of the participants i.e. community-based, 
institutionalized or hospitalised. Disruptive behaviour had to be diagnosed using 
established specified criteria. Studies that included both adults and children were 
excluded from this review if the data for the children could not be extracted. 
 
3.1.3. Types of interventions  
Risperidone by any means of delivery, dose and duration. The control group had to be 
either a placebo group, a wait-list control group or no treatment group. 
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3.1.4. Types of outcome measures  
 
T
S
N
A
B
C
S
E
 
O
M
V
M
P
W
 
 Primary outcomes  
   Disruptive behaviour (aggression to others, non-aggressive challenging 
behaviour, aggression to self) 
Secondary outcomes  
  Adverse effects  
 
ypes of measurement instruments 
tandardised diagnostic assessment instruments for primary outcomes: 
isonger Child Behaviour Rating Form (NCBRF) 
berrant Behaviour Checklist (ABC) 
ehaviour Problem Inventory (BPI) 
linical Global Impressions Scale (CGI) 
tandardised diagnostic assessment instrument for secondary outcomes: 
xtrapyramidal Symptom Rating Scale (ESRS) 
ther measurement instruments 
easurement of primary outcomes: 
isual Analogue scale (VAS) 
easurement of secondary outcomes:  
rolactin level 
eight gain 
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3.2. SEARCH METHODS FOR IDENTIFICATION OF STUDIES  
 
3.2.1. Electronic searches  
Relevant trials were identified by searching the following databases. No language 
restrictions were applied: 
CENTRAL (Cochrane Central Register of Controlled Trials) 2009  
MEDLINE, with OVID online (1966 to June 2009) 
PsycINFO, with OVID (1887 to June 2009) 
CINAHL, with EBSCO online (1982 to June 2009) 
Clinicaltrials.gov (USA) (June 2009) 
National Research Register (NRR) (UK) 2009  
 
Search strategies 
The search strategies were designed to be both sensitive and specific. The specific 
search strategy to identify randomised controlled trials, as recommended in the 
Cochrane Handbook for Systematic Reviews of Interventions in Box 6.4.a, was used 
in conjunction with medical subject headings and text words specific for learning 
disability and risperidone (Higgins 2008). When searching different databases, the 
search terms and strategies were changed to the appropriate syntax to search the 
appropriate fields. No language restrictions were applied. 
 
Search terms for CENTRAL were as follows: 
(mental-retardation*: ME or mentally-disabled-persons*:ME or (learning or mental* 
or intellect* or cognitiv*) near (difficult* or handicap* or retard* or disable* or 
disabilit* or deficien* or incapacit* or impair*) or (subnormal* next cognit*) or 
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(subnormal* near intel*) or (subnormal* near mental*) or (education* near 
subnormal*)) and (antipsycho* or anti-psycho* or ANTIPSYCHOTIC AGENT or 
atypical anti-psycho* or atypical antipsycho* or risperidone or risper*) 
 
Search terms for MEDLINE were as follows: 
1     randomized controlled trial.pt. 
2     controlled clinical trial.pt. 
3     randomized.ab. 
4     placebo.ab. 
5     drug therapy.fs. 
6     randomly.ab. 
7     trial.ab. 
8     groups.ab. 
9     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10     humans.sh. 
11     9 and 10 
12     risperidone.mp. 
13     risper$.mp. 
14     106266-06-2.rn. 
15     or/12-14 
16     exp mental retardation/ 
17     exp Learning Disorders/ 
18     mentally disabled persons/ 
19     ((learn$ or mental$ or intellect$ or cognitive$) adj3 (difficult$ or disable$ or 
disabilit$ or disorder$ or deficien$ or incapacit$ or retard$ or handicap$ 
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or impair$)).tw. 
20     ((subnormal$ or subaverage) adj3 (intel$ or cognit$ or mental$)).tw. 
21     (education$ adj3 subnormal$).tw. 
22     or/16-21 
23     11 and 15 and 22 
24     limit 23 to animal 
25     23 not 24 
 
Search terms for PsychINFO were as follows: 
1 randomized 
2 controlled clinical trial 
3 randomized.ab. 
4 placebo.ab. 
5 drug therapy.ab. 
6 randomly.ab. 
7 trial.ab. 
8 groups.ab. 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10 (((mental* or learning or intell* or cognive*) AND (handicap* or retard* or disab* 
or difficult* or impair* or subnormal*)) or oligophren* or (mental* or learning or 
intell* or cognive*) AND (handicap* or retard* or disab* or difficult* or impair* or 
subnormal*)) 
11 explode 'Mental-Retardation' in DE 
12 explode 'Learning-Disorders' in DE 
13 (antipsycho* or anti-psycho* or neuroleptic* or risperidone*) 
 28
14 explode 'Neuroleptic-Drugs' in DE 
15 or/10-12 
16 13 or 14 
17 9 and 15 and 16 
Search terms for CINAHL were as follows: 
(mental-retardation* OR mentally-disabled-persons* OR cognitiv* impair* OR 
subnormal* intel* OR (learning OR mental* OR intellect* OR cognitiv*) AND 
(difficult* OR handicap* OR retard* OR disable* OR disabilit* OR deficien* OR 
incapacit* OR impair* )) 
AND (antipsycho* OR anti-psycho* OR ANTIPSYCHOTIC AGENT* OR atypical 
anti-psycho* OR atypical antipsycho* OR risperidone OR risper*) 
 
3.2.2. Searching other resources  
The papers identified through the above search strategy were screened for additional 
relevant references and their eligibility assessed for inclusion in this review. The 
references of narrative reviews on this topic were also searched for relevant studies. 
Handsearches were done on the journals American Journal on Intellectual and 
Developmental Disabilities (1993 - 2009) (previously known as the American Journal 
of Mental Retardation) and the Journal of Intellectual Disability Research (1993 - 
2009), as risperidone was first approved for use in 1993 by the FDA and it is highly 
improbable that studies would have used the drug before then. No language 
restrictions were applied. Ortho-McNeil-Janssen Pharmaceuticals, Inc. the 
pharmaceutical manufacturers of Risperdal, was contacted to obtain data regarding 
unpublished and ongoing trials. 
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3.3. DATA COLLECTION AND ANALYSIS  
 
3.3.1. Selection of studies  
Studies eligible for inclusion in this review were all published and unpublished 
randomised controlled trials and quasi-randomised controlled trials that included 
information on children and adolescents with learning disability who received 
risperidone as treatment for disruptive behaviour, identified by the previously 
described search strategies. The identified titles and available study abstracts were 
screened by the author and checked independently by the supervisor (AC) to create a 
pool of eligible studies. Full-text articles were obtained for all titles and abstracts 
considered relevant and an eligibility form was completed for each of the relevant 
studies. Any disagreements on the eligibility of any study were resolved by 
discussion. A study that did not fulfil the inclusion criteria were excluded from this 
review. Additional information from trial authors were requested where published 
results did not allow accurate assessment of eligibility. 
 
3.3.2. Data extraction and management  
The author extracted the data on study design, participants, and outcome measures 
using a pre-designed data collection form, and was then checked by the supervisor 
(AC) for accuracy. At data extraction the study's eligibility was reassessed. All data 
was entered and organised using Review Manager 5 (RevMan 2008). All data was 
double-checked for accuracy at data entry. If two or more homogenous studies met 
the inclusion criteria and reported the same outcome measures using the same scale, a 
meta-analysis was performed. The statistical analysis was performed by using 
RevMan 5. 
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3.3.3. Assessment of risk of bias in included studies  
The methodological quality of the selected studies was assessed using standard 
quality assessment criteria according to the guidelines in the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins 2008). Individual study quality was 
assessed by reviewing the generation of allocation sequence, allocation concealment, 
blinding, incomplete outcome data, selective outcome reporting and other bias. Where 
inadequate details of randomization and other characteristics of trials were reported, 
the authors were contacted in order to obtain further information. 
 
Adequate sequence generation was assessed as "Yes", "No" and "Unclear". 
• Criteria to be judged as "Yes", indicating low risk of bias: 
Random number table, computer generated random numbers, coin tossing, shuffling 
cards or envelopes, throwing dice, drawing of lots, minimization. 
• Criteria to be judged as "No", indicating high risk of bias: 
Sequences generated by a non-random process like dates of birth, admission date, 
hospital record number or clinician discretion. 
• Criteria to be judged as "Unclear", indicating uncertain risk of bias: 
Not enough information available to be judged as "yes" or "no". 
 
Adequate allocation concealment was assessed as "Yes", "No" and "Unclear". 
• Criteria to be judged as "Yes", indicating low risk of bias: 
Neither investigators nor enrolling participants could predict assignment to groups. 
Using methods such as central allocation, sequentially numbered identical drug 
containers, sequentially numbered opaque sealed envelopes. 
• Criteria to be judged as "No", indicating high risk of bias: 
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Either investigators or enrolling participants could possibly predict assignment to 
groups, introducing selection bias. Using methods such as an open random allocation 
list, non-opaque and unsealed envelopes, allocation on alternation or rotation, 
allocation on date of birth, allocation on hospital record number. 
• Criteria to be judged as "Unclear", indicating uncertain risk of bias: 
Not enough information available to be judged as "yes" or "no". 
 
Adequate blinding (participants, personnel and outcome assessors) was assessed as 
"Yes", "No" and "Unclear". 
• Criteria to be judged as "Yes", indicating low risk of bias: 
Certain blinding of participants and their caregivers, as well as key study personnel. 
• Criteria to be judged as "No", indicating high risk of bias: 
No blinding or incomplete blinding of participants or their caregivers, or the outcome 
assessors of the study. 
• Criteria to be judged as "Unclear", indicating uncertain risk of bias: 
Not enough information available to be judged as "yes" or "no". 
 
Incomplete outcome data (addressed) was assessed as "Yes", "No" and "Unclear". 
• Criteria to be judged as "Yes", indicating low risk of bias: 
No missing outcome data, missing outcome data balanced between groups, missing 
outcome data unrelated to key outcomes, missing data appropriately and correctly 
imputed. 
• Criteria to be judged as "No", indicating high risk of bias: 
Missing data crucial to key outcomes, overall attrition >20%, missing data cause a 
mismatch of participant numbers between intervention and comparison groups 
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(attrition difference >10% between groups), missing data inappropriately and 
incorrectly imputed. 
• Criteria to be judged as "Unclear", indicating uncertain risk of bias: 
Not enough information available to be judged as "yes" or "no". 
 
Selective outcome reporting (addressed) was assessed as "Yes", "No" and "Unclear". 
• Criteria to be judged as "Yes", indicating low risk of bias: 
All predefined and expected primary and secondary outcome data reported. 
• Criteria to be judged as "No", indicating high risk of bias: 
Not all of the predefined and expected primary and secondary outcome data reported, 
some primary outcomes reported using measurements and scales not predefined, 
reporting outcomes not pre-specified, one or more key outcome data incompletely 
reported. 
• Criteria to be judged as "Unclear", indicating uncertain risk of bias: 
Not enough information available to be judged as "yes" or "no". 
 
Free of other bias was assessed as "Yes", "No" and "Unclear". 
• Criteria to be judged as "Yes", indicating low risk of bias: 
Study seems free of other sources of bias that could have compromised the validity of 
the study. 
• Criteria to be judged as "No", indicating high risk of bias: 
Study has at least one important risk of bias that could have compromised the validity 
of the study - such as crucial study design flaw, extreme baseline inequality between 
intervention groups, fraudulent claims. 
• Criteria to be judged as "Unclear", indicating uncertain risk of bias: 
Not enough information available to be judged as "yes" or "no". 
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3.3.4. Measures of treatment effect  
Binary data - where the outcomes from either standardised instrument scales or 
diagnostic evaluations were expressed as proportions, results were expressed as 
relative risks (RR), at a conventional significance level of 5 % (α=0.05, 95% 
confidence interval). 
 
Continuous data - where a score was the outcome measure of a standardised 
assessment tool, comparisons were made between the means of these scores. If 
outcome measures were on the same scales, a meta-analysis was performed using a 
'weighted' mean difference, at a conventional significance level of 5 % (α=0.05, 95% 
confidence interval).  
 
3.3.5. Unit of analysis issues  
The studies included in this systematic review had a standard simple parallel group 
design, no non-standard designed studies i.e. cross-over, cluster-randomised trials, 
were found eligible to be included. Thus each study represented a unit in the analysis, 
where the participants were allocated to a placebo control group or to a risperidone 
intervention group and only compared to the other participants within that study and 
not with participants from any other trial. 
 
3.3.6. Dealing with missing data  
All missing data and trial drop-outs were reported in the review. Missing statistics, 
such as standard deviations or correlation coefficients, and insufficient data were 
requested from the relevant trial authors. Where these data were unavailable or 
unobtainable, the available data were still included in the review if possible; if not 
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possible the results of these studies were summarized in the text of the review. In the 
case of unreported standard deviations or if a study reported only standard errors, the 
standard deviations were calculated from the available study data, as described in the 
Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). 
 
3.3.7. Assessment of heterogeneity  
Heterogeneity in the results of included studies was assessed using the I2 measure 
(Higgings 2002) and the Chi squared test of heterogeneity and also by visual 
assessment of the graphical display of data in the forest plots. In the presence of 
significant heterogeneity (i.e. p<0.1, I2 > 50%), the accuracy of the data was checked 
to exclude a data capturing error. A fixed-effect method of meta-analysis was used for 
summarizing the results of the included studies as there was no significant 
heterogeneity between trial results. 
 
3.3.8. Assessment of reporting biases  
Every attempt has been made to identify unpublished studies. One such a study (Read 
2008) was found. A funnel plot was not considered to be appropriate to assess 
reporting bias in this review due to the limited number of included studies. 
 
3.3.9. Data synthesis  
Meta-analyses could be performed for the primary outcome of the review, disruptive 
behaviour, using four outcome measures (Nisonger Child Behaviour Rating Form 
(NCBRF), Aberrant Behaviour Checklist (ABC), Clinical Global Impression Scale - 
Improvement (CGI-I), Behaviour Problem Inventory (BPI)) and for three of the 
secondary outcomes of this review (Adverse effects - Extrapyramidal symptom - 
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Parkinsonism; Weight gain; Prolactin level). A fixed-effects model was used.  
 
3.3.10. Subgroup analysis and investigation of heterogeneity  
Sub-group analyses were planned a priori: 
1.  Level of learning disability  
2. Risperidone therapy in conjunction with behavioural therapies compared to 
risperidone treatment alone 
No subgroup analyses could be performed in this review as data were not reported in 
such a manner that allowed further analysis. 
 
3.3.11. Sensitivity analysis  
The robustness of the review conclusions was intended to undergo further sensitivity 
analyses i.e. comparing studies with high risk of bias to studies with low risk of bias, 
and also comparing industry sponsored studies to non-industry sponsored studies. 
However, insufficient data were available to perform these sensitivity analyses to 
assess how the study quality would affect the meta-analysis. 
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4. RESULTS  
4.1. DESCRIPTION OF STUDIES  
 
4.1.1. Results of the search  
The search strategies were performed in June 2009. The following citations were 
identified: 203 in MEDLINE, 109 in CENTRAL, 181 in CINAHL, 78 in PsycINFO. 
Only 63 citations qualified for further inspection. The references of the identified 
publications were also screened for other publications that might have been relevant 
to this review. Two authors (Tyrer P, Pandina G) responded to a request for 
information on other and unpublished studies. 
 
4.1.2. Included studies  
Four studies were eligible to be included in this review (Aman 2002; Buitelaar 2001; 
Snyder 2002; Van Bellinghen 2001). The studies were described as randomised and 
double-blind. Participants were children and adolescents between 5 and 14 years of 
both sexes, with a diagnosis of learning disability and reports of disruptive behaviour. 
A summary of the details of the included studies can be viewed in Table A1 in 
Appendix A (Characteristics of Included Studies). 
 
Participants 
A total of 279 participants received treatment (133 risperidone and 146 placebo) in 
the four studies combined. The number of participants in the studies were relatively 
small, ranging from 13 (Van Bellinghen 2001); 38 (Buitelaar 2001); 110 (Snyder 
2002); to 118 (Aman 2002). Notably 228 (81.7%) participants in this review are 
drawn from the two larger studies (Aman 2002; Snyder 2002). All the trials stated the 
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age range of the participants to be between 5 to 14 years. In addition, all studies stated 
the gender distribution of participants (218 male, 61 female) and all four trials had 
well defined inclusion and exclusion criteria. All the participants in the Buitelaar 2001 
study were hospitalised, most of the participants in the Snyder 2002 study were living 
at home with parents, and while the Aman 2002 and Van Bellinghen 2001 studies did 
not  describe the exact location of their study participants, it is  highly improbable  
that they were either hospitalised or institutionalised. The participants in the study by 
Buitelaar 2001 were institutionalized for very severe aggressive behaviour that was 
refractory to treatment. The average period of institutionalization was two years. 
 
Intervention 
Risperidone was the sole intervention with placebo being used as the comparison in 
all the included studies. The dosing and duration of the risperidone treatment varied 
between the studies, with a range of 0.01 mg/kg/day to 0.09 mg/kg/day. Three trials 
administered the risperidone/ placebo for 6 weeks (Aman 2002; Buitelaar 2001; 
Snyder 2002), and one study for 4 weeks (Van Bellinghen 2001). All studies used the 
oral form of risperidone. 
 
Outcomes 
All four included studies used the improvement of disruptive behaviour or aggression 
in children with learning disability as a primary outcome. These behaviours were also 
the major inclusion criteria for this review. The studies used both validated and 
unvalidated scales as outcome measures. These are listed in Table 7 and described in 
more detail below. 
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Table 7.  Scales & measures used in the studies 
Scale / measure 
Aman 
2002 
Buitelaar 
2001 
Snyder 
2002 
Van 
Bellinghen 
2001 
Aberrant Behaviour 
Checklist (ABC)  
Yes Yes Yes Yes 
Behaviour Problems 
Inventory (BPI) 
Yes - Yes - 
Clinical Global 
Impression (CGI)  
Yes Yes Yes Yes 
Extrapyramidal 
Symptom Rating Scale 
for Children (ESRS)  
Yes Yes Yes Yes 
Nisonger Child 
Behaviour Rating Form  
Yes - Yes - 
Overt Aggression Scale 
– Modified OAS-M  
- Yes - - 
Personal Assessment 
Checklist (PAC) 
- - - Yes 
Visual Analogue Scale – 
Parent rated (most 
troublesome symptoms) 
Yes - Yes - 
 
Validated Scales 
Nisonger Child Behaviour Rating Form (NCBRF) (Aman 1996) 
This instrument is used to assess behaviour severity and change in children with 
developmental disabilities. A Parent and Teacher version are available. The Parent 
NCBRF consists of 2 positive social subscales and 6 problem behaviour subscales. 
The positive/social subscales are as follows: 1) Compliant/Calm, and 2) Adaptive 
Social. The categories are presented in a question format and allow awarding of high 
scores to good behaviour.  The score for each subscale item ranges from 0 (indicating 
"not true") to 3 ("always true"). A high score indicates less severe symptoms. 
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The Problem Behaviour subscales are: 1) Conduct problems, 2) Insecure/Anxious, 3) 
Hyperactive, 4) Self-injury/ Stereotypic, 5) Self-isolating/ Ritualistic, 6) Overly 
sensitive. There are 66 question items, with a score for each item ranging from 0 
(indicating "no problem") to 3 ("severe problem"). Unlike the social subscales, a high 
score achieved on the Problem Behaviour subscale indicate severe symptoms. 
 
Aberrant Behaviour Checklist (Aman 1986) 
This behaviour assessment instrument assesses the efficacy of behaviour management 
in individuals with developmental disabilities. It is comprised of 5 subscales, with 58 
subcategories in total viz. 1) Irritability (15 items), 2) Lethargy/Social withdrawal (16 
items), 3) Stereotypic Behaviour (7 items), 4) Hyperactivity/ Non-compliance (16 
items), and 5) Inappropriate speech (4 items). The score for each item begins at 0 
indicating " no problem" with the highest score indicating a  "severe problem". A high 
score on the ABC denotes severe symptoms. 
 
Clinical Global Impression Scale (Guy 1976) 
This scale is used to assess the severity of illness and the response to treatment in 
individuals with mental illness. It is made up of three categories viz. 1) Severity of 
Illness, 2) Global Improvement, 3) Efficacy Index. The first item is rated on a seven-
point scale (1=normal to, 7=extremely ill); Item 2 has a seven-point scale (1=very 
much improved, to 7=very much worse); and Item 3 is comprised of a four-point scale 
(from "none" to "outweighs therapeutic effect"). The scales are often used 
individually. The utility of the scale is in the clinical setting to assess by how much 
the patient's symptoms have improved or worsened compared to a baseline state. Low 
scores indicate a decrease in the severity of symptoms. 
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Behaviour Problem Inventory (Rojahn 2001) 
This instrument is used to assess aggression, self-injury and stereotypic behaviour in 
individuals with developmental disabilities. 
 
Extrapyramidal Symptom Rating Scale (Chouinard 1980) 
The extrapyramidal symptom rating scale is used to assess the presence and severity 
of extrapyramidal symptoms in an individual. It consists of 5 sections each comprised 
of subsections viz. 1) Open-ended questions addressed to the individual or carer 
regarding extrapyramidal symptoms (12 items), 2) Parkinsonism section (8 items), 3) 
Dystonia section (2 items), 4) Dyskinesia section (7 items), 5) Global impression of 
overall severity of parkinsonism and dyskinesia. 
 
Unvalidated Scales 
Overt Aggression Scale (OAS-M) (Yudofsky 1986) 
This scale is used to assess aggression and violence in an individual. Four types of 
aggression are scored on a 4-point scale viz. 1) Verbal aggression, 2) Destruction of 
property, 3) Aggression to self, 4) Physical violence. The total score ranges from 0 to 
16, with a high score indicating severity of symptoms. 
 
Visual Analogue Scale (VAS) 
The VAS / Symptom tool is used to measure the rating of the severity of the most 
troublesome symptom in a participant. Observations by the carer or parent are 
recorded and rated. The VAS/ Sedation tool is used to measure the rating of the 
severity of sedation in a participant. Observations by the carer or parent are recorded 
and rated. 
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 Personal Assessment Checklist (PAC) 
Unvalidated scale not used often in clinical practice or research (Ettinger 2006). 
 
4.1.3. Excluded studies  
Twenty six studies did not meet the inclusion criteria for this review and were 
therefore excluded from this review. The full list of excluded studies and their reason 
for exclusion are reported in Table A2 in Appendix A (Characteristics of Excluded 
Studies). The most common reason for exclusion was because they were open label 
trials and not randomised controlled trials. 
 
 
4.2. RISK OF BIAS IN INCLUDED STUDIES  
Only one study reported adequate sequence generation (Snyder 2002), but did not 
report sufficient details to assess allocation concealment. None of the included studies 
reported sufficient information to assess adequate allocation concealment. Two 
studies described blinding briefly but adequately (Aman 2002; Snyder 2002).  
 
All studies reported attrition rates and causes of attrition; and used an intention-to-
treat analysis. Two studies were reviewed to have a low risk of bias as assessed by 
their reporting of incomplete outcome data (Buitelaar 2001; Van Bellinghen 2001). 
All participants completed the Van Bellinghen 2001 study, 2 participants receiving 
placebo withdrew from the Buitelaar 2001 study early (before the end of the double-
blind period) and 1 participant on risperidone withdrew during the washout period. 
Two studies were reviewed to have a high risk of bias when assessing their attrition 
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rates (Aman 2002; Snyder 2002).  Thirty one of the 118 participants did not complete 
the study with an overall attrition rate of 26% in the Aman 2002 study. There was a 
noticeable difference between the attrition numbers in the risperidone (12/55 (21 %)) 
and placebo (19/63 (30 %)) groups. The reasons for early withdrawal differed 
between the risperidone and placebo groups. In the risperidone group the reasons for 
attrition were reported as; 4 (7.3%) insufficient response; 3 (5.5%) non-compliance; 2 
(3.6%) adverse events; 1 (1.8%) lost to follow up (LTFU); 1 (1.8%) consent 
withdrawn; 1 (1.8%) medication lost. In the placebo group the reasons for attrition 
were reported as; 15 (23.8%) insufficient response; 3 (4.8%) lost to follow up; 1 
(1.6%) consent withdrawn. The study excluded three risperidone participants on 
whom no outcome data were collected from the efficacy analysis.  However, these 
participants appeared not to have been included in the study’s attrition report. A 
recalculation shows that the total risperidone attrition rate could be slightly higher 
with figures of 15/55 (27%).  In the Snyder 2002 study, 25 out of the 110 participants 
did not complete the study, with an overall attrition rate of 22.7%. There was a 
noticeable difference between the attrition numbers in the risperidone (6/53 (11.3 %)) 
and placebo (19/57 (33.3 %)) groups.  The reasons for early withdrawal in the 
risperidone group were reported as; 2 (3.8%) insufficient response; 1 (1.9%) lost to 
follow up; 3 (5.7%) loss of consent. In the placebo group the reason was; 19 (33.3%) 
insufficient response. 
 
Three studies reported all outcomes (Aman 2002; Buitelaar 2001; Snyder 2002). It 
was unclear if any of the included studies were free of other bias, and all of the four 
studies were industry sponsored (Ortho-McNeil-Janssen Pharmaceuticals, Inc.). The 
risk of bias table for each included study is presented at the bottom of Table A1 in 
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Appendix A (Table of Characteristics of Included Studies). The summary of the risk 
of bias in all included studies is presented in Figure 2, Methodological quality 
summary. 
 
Figure 2.  Methodological quality summary 
 
 
 
4.3. EFFECTS OF INTERVENTIONS  
Four studies involving 279 participants were included in this systematic review. 
However, because of the variation in the presentation of results and data, all four 
studies were not able to be used simultaneously in the meta-analyses of each outcome 
measure. Limited analyses was possible using two to three of the studies for each of 
the five different measurement scales for the primary outcome and the secondary 
outcomes or adverse events which included weight gain, prolactin levels and an 
extrapyramidal symptom (parkinsonism) using the Extrapyramidal Symptom Rating 
Scale (ESRS). Primary and secondary outcome measurements and results are 
presented narratively, all the data tables are presented in Appendix B and all the 
forrest plots in Appendix C. 
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 4.3.1. Primary Outcome (disruptive behaviour) 
Disruptive behaviour as the primary outcome denominator was principally measured 
on the Nisonger Child Behaviour Rating Scale and then comparing the participants 
behaviour at baseline to their behaviour at study endpoint. The symptoms listed on the 
Nisonger conduct problem subscale correspond well with the diagnostic criteria of the 
DSM IV Disruptive behaviour disorders. Other behaviour assessment tools used were 
the Aberrant Behaviour Checklist (ABC); the Behaviour Problem Inventory (BPI); 
and the investigator’s rating on the Clinical Global Impression Improvement scale 
(CGI-I). Additionally, a change in the Visual Analogue Scale (VAS) rating of 
an individual target symptom reported by parents for each patient was assessed. The 
unvalidated Personal Assessment checklist (PAC) was only used by one study Van 
Bellinghen 2001, as was the Overt Aggression scale (OAS-M) (Buitelaar 2001) and 
their results reported narratively. Please refer to section 4.1.2 for the scales of 
measurement for the different measurement tools to interpret the size of differences in 
the mean scores. 
 
Nisonger Child Behaviour Rating form - NCBRF (Tassé 1996) 
For the Nisonger scale, meta-analysis was carried out on two studies (Aman 2002 and 
Snyder 2002) in which the parent version of the social competence and problem 
behaviours subscales was used. Snyder 2002 reported the means at baseline and 
endpoint, while Aman 2002 reported the change in means at endpoint. A fixed-effects 
model meta-analysis was used and a low degree of heterogeneity was found on most 
subscales as both studies were similarly designed and had similar sample populations. 
The results of the meta-analysis are as follows:  
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 Nisonger: Social Competence Subscale 01:  Compliant/calm 
The analysis of the compliant/calm subscale yielded a mean positive score of 1.89 
higher on risperidone than on placebo [95% CI = 0.94, 2.84 (p < 0.0001)]. The Chi² 
test for Heterogeneity was 0.09 on 1 degree of freedom (p = 0.77) and the I² was 0% 
for this outcome. 
Nisonger: Social Competence Subscale 02: Adaptive/social 
The analysis of the adaptive/social subscale yielded a mean positive score 1.54 higher 
on risperidone than on placebo [95% CI = 0.88, 2.20 (p < 0.00001)]. Chi² test for 
Heterogeneity = 0.02, df = 1 (p = 0.88); I² = 0%. 
Nisonger: Problem Behaviours Subscale 01:  Conduct problem 
The analysis of the conduct problem subscale, the principle measure of the primary 
outcome in this review,  yielded a mean positive score -8.67 lower on risperidone than 
on placebo [95% CI = -11.72, -5.62 (p < 0.00001)]. Chi² test for Heterogeneity = 0.06, 
df = 1 (p = 0.80); I² = 0%. 
Nisonger: Problem Behaviours Subscale 02:  Insecure/anxious 
The analysis of the insecure/anxious subscale yielded a mean positive score -4.24 
lower on risperidone than on placebo [95% CI = -6.13, -2.35 (p < 0.0001)]. Chi² test 
for Heterogeneity = 1.54, df = 1 (p = 0.21); I² = 35%. 
Nisonger: Problem Behaviours Subscale 03:  Hyperactive 
The analysis of the hyperactive subscale yielded a mean positive score -2.84 lower on 
risperidone than on placebo [95% CI = -4.39, -1.30 (p = 0.0003)]. Chi² test for 
Heterogeneity = 1.40, df = 1 (p = 0.24); I² = 28%. 
Nisonger: Problem Behaviours Subscale 04:  Self-injury/stereotypic 
The analysis of the self-injury/stereotypic subscale yielded a mean positive score -
0.83 lower on risperidone than on placebo [95% CI = -1.71, 0.05 (p = 0.06)]. Chi² test 
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for Heterogeneity = 0.31, df = 1 (p = 0.58); I² = 0%. 
Nisonger: Problem Behaviours Subscale 05:  Self-isolated/ritualistic 
The analysis of the self-isolated/ritualistic subscale yielded a mean positive score -
1.47 lower on risperidone than on placebo [95% CI = -2.45, -0.48 (p = 0.004)]. Chi² 
test for Heterogeneity = 0.09, df = 1 (p = 077); I² = 0%. 
Nisonger: Problem Behaviours Subscale 06:  Overly sensitive 
The analysis of the overly sensitive subscale yielded a mean positive score -0.95 
lower on risperidone than on placebo [95% CI = -1.87, -0.04 (p = 0.04)]. Chi² test for 
Heterogeneity = 7.07, df = 1 (p = 0.008); I² = 86%. 
 
Both Aman 2002 and Snyder 2002 reported benefit in the two positive/social 
subscales that assigned higher scores to improved behaviour, with a similar 
statistically significant overall summary effect of benefit. The summary effect also 
showed benefit in all the problem behaviour subscales that assigned lower scores to 
improved behaviour. All meta-analyses of problem behaviour subscales were 
statistically significant at a level of 95% confidence interval except for the self-
injury/stereotypic subscale which was marginally statistically insignificant (p=0.06). 
 
Aberrant Behaviour Checklist- ABC (Aman 1986) 
For this validated scale, meta-analysis was possible as Aman 2002, Buitelaar 2001 
and Snyder 2002 all used the measurement throughout its five subscales. Van 
Bellinghen 2001 used this scale, but did not report any standard deviations or enough 
data to calculate standard deviations. Two of the ABC subscales (irritability and 
stereotypy) are measures of disruptive behaviour which is the primary outcome. 
Although Buitelaar 2001 and Snyder 2002 reported the means at baseline and 
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endpoint, and Aman 2002 reported the change in means at endpoint, the data could 
still be combined in a fixed-effects model meta-analysis with the results below. A 
numerical error was found in the irritability subscale data point of ABC in Snyder 
2002, however the correct figure was obtained from the text.   
  
ABC Subscale 01: Irritability 
The analysis of the ABC subscale of irritability yielded a mean score on risperidone 
of -4.00 lower than on placebo [95% CI = -6.07, -1.92 (p = 0.0002)]. Chi² test for 
Heterogeneity =2.40, df= 2 (p = 0.30) and the I² was 17% for this outcome. 
ABC Subscale 02: Social withdrawal/ Lethargy 
The analysis of the ABC subscale of social withdrawal/lethargy yielded a mean score 
on risperidone of -2.55 lower than on placebo [95% CI = -4.07, -1.02 (p = 0.001)]. 
Chi² test for Heterogeneity = 0.63, df = 2 (p = 0.73); I² = 0%. 
ABC: Subscale 03: Hyperactivity 
The analysis of the ABC subscale of hyperactivity yielded a mean score on 
risperidone of -0.77 lower than on placebo [95% CI = -1.68, 0.13 (p = 0.09)]. Chi² test 
for Heterogeneity = 0.03, df = 2 (p = 0.98); I² = 0%. 
ABC: Subscale 04: Stereotypy 
The analysis of the ABC subscale of stereotypy yielded a mean score on risperidone 
of -6.65 lower than on placebo [95% CI = -9.24, -4.05 (p < 0.00001)]. Chi² test for 
Heterogeneity = 3.88, df = 2 (p = 0.14); I² = 48%. 
ABC: Subscale 05: Inappropriate speech 
The analysis of the ABC subscale of inappropriate speech yielded a mean score on 
risperidone of 0.77 higher than on placebo [95% CI = 0.15, 1.40 (p = 0.02)]. Chi² test 
for Heterogeneity = 30.58, df = 2 (p < 0.00001); I² = 93%. 
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 The results of the ABC irritability and stereotypy subscales appear to significantly 
favour risperidone compared to placebo, at a level of 95% confidence interval. The 
results of the social withdrawal / lethargy subscale were also significantly in favour of 
risperidone, but the changes in the hyperactivity and inappropriate speech subscales 
were not significant. The markedly high heterogeneity (I² = 93%) in the analysis of 
the inappropriate speech subscale was an unexpected finding compared to the other 
subscales and the cause remains unclear. A change in the effects model of analysis 
does not change the heterogeneity of this subscale significantly. The result of the 
inappropriate subscale should thus be interpreted with caution, although the very low 
heterogeneity on all the other subscales is reassuring to validate the results of each 
subscale, as well as those of the primary outcome. 
 
Behaviour Problems Inventory Subscale (BPI)  (Rojahn 2001) 
Aman 2002 and Snyder 2002 were the only two studies to report data using the BPI 
scale, allowing a meta-analysis to be performed across its three subscales. The first 
two subscales (“aggressive / destructive” and “self-injurious”) recognize the key 
features of disruptive behaviour which is the primary outcome in this study review: 
  
BPI Subscale 01: Aggressive/ destructive 
The analysis of the aggressive/ destructive subscale yielded a mean score of -4.96 
lower on risperidone than on placebo [95% CI = -7.31, -2.61 (p < 0.0001)]. The Chi² 
test for Heterogeneity was 0.25 on 1 degree of freedom (p = 0.62) and the I² was 0% 
for this outcome. 
BPI Subscale 02: Self-injurious 
The analysis of the self-injurious subscale yielded a mean score -0.41 lower on 
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risperidone than on placebo [95% CI = -2.12, 1.29 (p = 0.63)]. Chi² test for 
Heterogeneity = 0.03, df = 1 (p = 0.87); I² = 0%. 
BPI Subscale 03:  Stereotyped 
The analysis of the stereotyped subscale yielded a mean score -0.38 lower on 
risperidone than on placebo [95% CI = -1.46, 0.69 (p = 0.48)]. Chi² test for 
Heterogeneity = 0.53, df = 1 (p = 0.47); I² = 0%. 
The result of the BPI aggressive / destructive subscale appears to significantly favour 
risperidone compared to placebo, at a level of 95% confidence interval. The changes 
in the self-injurious and stereotyped subscales were not significant. 
 
Clinical Global Impression Scale -CGI scale (Guy 1976) 
Although the CGI scale was used by all four studies, (Buitelaar 2001) was the only 
study to report on the Severity scale without the Improvement scale. The data 
collected in the seven point Improvement scale in Aman 2002, Snyder 2002 and Van 
Bellinghen 2001 was reported on different ways in each study. Van Bellinghen 2001 
combined the seven points into two categories, but no standard deviations were 
reported, so it could not be included in a meta-analysis. The data from Aman 2002 
and Snyder 2002 was converted into two categories comparing "much worse / worse / 
unchanged" to "minimally improved/ moderately improved / much improved / very 
much improved".  With the data in binary form, the relative risk (Mantel-Haenszel 
Risk Ratio) of improvement in the CGI-I was shown to be 2.69 [95% CI = 2.00, 3.62 
(p < 0.00001)], indicating a significant difference between the use of risperidone and 
placebo, favouring risperidone. Heterogeneity did not appear sizeable (Chi² = 1.19, df 
= 1 (p = 0.28); I² = 16%). 
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Visual Analogue Scale for most severe symptoms (caregiver)  
The VAS is an unvalidated and relatively inaccurate test for assessing change in 
behaviour by caregivers, however it was used as a secondary efficacy measure of the 
primary outcome in Aman 2002 and Snyder 2002. Meta-analysis was possible and 
showed a significant difference between groups, favouring risperidone, with a mean 
score of -22.56 mm lower on the 100 mm scale at endpoint [95% CI = -24.09, -21.02 
(p < 0.00001)], however there was moderate to substantial Heterogeneity (Chi² = 
1.90, df = 1 (p = 0.17); I² = 47%) 
 
Study results not included in meta-analyses 
Results from Buitelaar 2001 for the OAS-M showed that risperidone treatment was 
associated with a significant reduction of the overall score (p<0.01), as well as in the 
physical aggression subscale (p < 0.001) and aggression to property subscale (p < 
0.01). Results from Van Bellinghen 2001 for the PAC showed that risperidone was 
significantly superior than placebo in the social relationship subscale (p < 0.05) and 
occupational attitudes (p < 0.05). Neither of these two subscales are core diagnostic 
features of disruptive types of behaviours. 
 
4.3.2. Secondary Outcomes 
Adverse events 
Adverse events were reported in 117 participants (88.0%) in the risperidone groups 
and 103 (70.5%) in the placebo groups in total in the four studies. The numbers of 
adverse events in each study are presented in Table 8 below; however the authors 
included mild, moderate and severe adverse effects together in this data. Two 
participants discontinued treatment and withdrew from one study (Aman 2002) 
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because of adverse events (significant somnolence in both cases). No other 
participants withdrew due to adverse effects in the other three studies. Adverse effects 
of importance or clinical significance such as extrapyramidal symptoms, weight gain, 
sedation/ somnolence and prolactin levels are presented in detail below.   
 
Table 8.  Number of adverse events (%) in risperidone and placebo groups 
Study Risperidone Placebo 
Aman 2002 54 / 55 (98%) 44 / 63 (70%) 
Buitelaar 2001 17 / 19 (89%) 11 / 19 (58%) 
Snyder 2002 42/ 53 (79%) 46 / 57 (81%) 
Van Bellinghen 2001 4 / 6  (67%) 2 / 7   (29%) 
Total 117 / 133 (88%) 103 / 146 (71%) 
 
Extrapyramidal Symptom Rating Scale for Children (ESRS) 
All four studies used the ESRS to assess extrapyramidal symptoms in the risperidone 
and placebo groups. All four studies reported no significant between-group 
differences in extrapyramidal symptoms on any indicator of the ESRS scale, however 
only Aman 2002 presented complete data. Buitelaar 2001 reported data for the 
parkinsonism subscale of the ESRS, and thus meta-analysis was possible only for this 
indicator, showing no significant difference between the groups (p = 0.85). Only one 
participant in Snyder 2002 and one participant in Buitelaar 2001 were rated as 
developing tardive dyskinesia and orofacial dyskinesia respectively, however these 
participants were both receiving placebo. No participants in any of the studies 
required medication to treat extrapyramidal symptoms.  
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Weight 
Aman 2002, Buitelaar 2001 and Snyder 2002 each showed significant increases in 
mean difference in weight in participants on risperidone compared to placebo (1.30 
kg, 1.70 kg and 2.00 kg respectively), while Van Bellinghen 2001 showed no 
statistical significant difference at endpoint. All four studies reported extractable data 
for weight of participants at endpoint, allowing meta-analysis using all participant 
data, resulting in a significant increase of 1.46 kg in mean difference in weight for 
participants on risperidone compared to placebo  [95% CI =0.96, 1.97 (p < 0.00001)]. 
Heterogeneity was negligible (Chi² = 1.23, df = 3 (p = 0.75); I² = 0%). 
 
Sedation / somnolence 
Aman 2002, Buitelaar 2001 and Snyder 2002 reported the number of adverse events 
of sedation or somnolence, with 52 (40.9%) participants in the three studies 
experiencing sedation in the risperidone groups versus 14 (10.1%) in the placebo 
groups in total. A fixed-effects meta-analysis showed a significant effect of sedation 
in those on risperidone versus placebo with a Mantel-Haenszel Risk Ratio of 4.00 
[95% CI =2.37, 6.76 (p < 0.00001)] with no substantial evidence of heterogeneity 
(Chi² = 1.20, df = 2 (p = 0.55); I² = 0%). 
 
Aman 2002 also used an unvalidated visual analogue scale for sedation (where higher 
scores are indicative of sedation), reporting mean scores of 5.90 for risperidone 
compared to –2.02 for placebo (F=7.43, df=1, 99, p= 0.008, ANCOVA with factors 
for site, baseline, and disorder). Aman 2002 reported that most cases of somnolence 
were mild, with only two cases reported as severe, but the authors did not specify in 
which group the severe cases were found. Van Bellinghen 2001 did not report 
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separate data for adverse events occurring in six participants in the study, but 
commented that all adverse events were mild except for somnolence, which was 
moderate.  
 
Prolactin 
Aman 2002 and Snyder 2002 both measured and reported prolactin levels separately 
for male and female participants, which were combined in a fixed-effects meta-
analysis. The mean difference in prolactin was 14.56 ng/mL higher at endpoint in 
female participants on risperidone versus placebo [95% CI =7.35, 21.76 (p < 0.0001)], 
however with substantial heterogeneity (Chi² = 2.87, df = 1 (P = 0.09); I² = 65%). In 
males, this difference was even higher, with those on risperidone having a mean 
difference in prolactin of 20.70 ng/mL higher at endpoint compared to placebo [95% 
CI =15.73, 25.68 (p < 0.00001)], with no evidence of heterogeneity (Chi² = 0.00, df = 
1 (P = 0.98); I² = 0%). Gynaecomastia, amenorrhoea, or other prolactin-related 
adverse events were not reported in any of the studies, although Snyder 2002 reported 
one case of dysmenorrhoea. 
 
Other adverse effects measures 
After the adverse effects reported above, the most common symptoms reported by the 
studies were headache, vomiting, dyspepsia, increased appetite and rhinitis. Data from 
two studies, Aman 2002 and Snyder 2002, have been collated and presented in Table 
9 below. The combined placebo group seems to have a markedly high prevalence of 
non-specific adverse effects, notably headaches (23.1% in placebo group versus 
10.8% in risperidone group). 
 
 54
Vital signs were measured in all studies. A temporary increase in heart rate of 11bpm 
was found in the first 2 weeks of treatment but not at endpoint in one study (Aman 
2002), while a smaller study of 13 participants found a 9.3 bpm increase at endpoint 
(p=0.05, Van Bellinghen 2001). No significant differences in diastolic blood pressure 
were found in any of the four studies.  
 
No abnormalities were detected on electrocardiography (ECG). ECG analyses 
specifically included the calculation of the QTc interval in two studies (Aman 2002, 
Snyder 2002).    
 
There were no clinically relevant mean changes in haematology, clinical chemistry 
(including electrolytes, liver function and thyroid tests), or urinalysis parameters in 
either of the groups reported in any of the studies.  
 
Snyder 2002 detected no significant cognitive changes due to drug condition on any 
of variables of the California Verbal Learning Test for Children (CVLT).  
 
Table 9.  Prevalence of other reported adverse events for risperidone and 
placebo in two studies (Aman 2002, Snyder 2002) 
 
Placebo (n = 108) Risperidone (n = 120) 
Adverse events 
N (%) n (%) 
Headache 25 23.1% 13 10.8% 
Vomiting 17 15.7% 8 6.7% 
Dyspepsia 16 14.8% 8 6.7% 
Increased appetite 14 13.0% 6 5.0% 
Rhinitis 13 12.0% 8 6.7% 
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5. DISCUSSION  
5.1. SUMMARY OF MAIN RESULTS  
 
5.1.1. Clinical therapeutic effects/ efficacy 
This systematic study review has shown that risperidone may be of some benefit for 
the management of certain types of disruptive behaviours in children and adolescents 
with learning disability, though the findings should be interpreted with caution. 
 
The meta-analyses of the primary outcome scales (Nisonger Child Behaviour Rating 
Form, Aberrant Behaviour Checklist, Behaviour Problem Inventory) measuring some 
core symptoms of disruptive behaviour, namely conduct problems, self-injury, 
irritability, aggressive/ destructive behaviours, stereotypy suggest statistically 
significant improvement in disruptive type behaviours in children treated with 
risperidone compared to placebo. Positive behaviours as measured on the Nisonger 
outcome measurement scale also showed a statistically significant improvement in the 
children treated with risperidone versus placebo. 
 
5.1.2. Adverse events 
As all the randomised controlled trials were of short duration, this review lacked 
adequate data to confidently comment on the magnitude of adverse effects and the 
long term safety profile of risperidone. The analysis of the adverse event data from 
the included studies showed that the prevalence of adverse effects viz. weight gain, 
sedation/ somnolence and raised prolactin level was significantly higher in the 
children receiving risperidone. 
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5.2. OVERALL COMPLETENESS AND APPLICABILITY OF EVIDENCE  
5.2.1. Age 
The age range of children in the four included studies was between 5 to 14 years, 
although those over 12 years old were not well represented overall. Therefore caution 
should be taken when considering the application of this review to younger children 
below 5 years or older children over the age of 12 years. 
 
5.2.2. Gender 
The gender distribution of participants was predominantly male, with 218 male 
participants and 60 female participants. This ratio approximates the 3:1 ratio of boys 
to girls diagnosed with conduct disorder (Sadock 2005), providing sufficient 
confidence of the relevance of the review.  
  
5.2.3. Geographic location 
The two larger studies from which 81.7% of participants were drawn for this review 
were carried out in North America (Aman 2002 in the USA and Snyder 2002 in 
Canada). The two studies in Central Europe only represented 18.3% of the 
participants in the review (Buitelaar 2001 in the Netherlands and Van Bellinghen 
2001 in Belgium). No details were provided on the ethnicity of the children recruited 
in the baseline characteristics of the studies. The applicability of this review to most 
regions outside of North America and in low resource healthcare settings may be 
limited.   
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5.2.4. Diagnostic criteria and measurements 
Study participants were categorised by classification of severity of IQ score using the 
DSM-IV classification system (APA 1994), not the most recent DSM-IV TR system 
(APA 2000).  The majority of participants were categorised as borderline severity (IQ 
70 – 85). Severe and profound learning disability (IQ < 35) were not represented in 
any of the studies, and thus the applicability of this review is limited to higher 
functioning children with borderline, mild and moderate learning disability.  
 
Three of the studies (Aman 2002; Buitelaar 2001; Snyder 2002), representing 95.3% 
of the participants in the review, used the DSM-IV system to classify disruptive 
behaviours, categorizing the children into three groups:  (i) oppositional defiant, (ii) 
conduct disorder, (iii) disruptive behaviour disorder not otherwise specified (APA 
1994).  Van Bellinghen 2001 used a list of persistent behavioural disturbances, some 
of which correspond to the symptom criteria used in the DSM-IV system. Although 
the DSM-IV classification system was used in these studies, its use in clinical practice 
is often limited in children with learning disabilities (Rush 2000; Tyrer 2008). The 
evidence for the use of risperidone in this review is therefore limited to children with 
learning disabilities who have met sufficient criteria for the DSM-IV classification of 
oppositional defiant, conduct disorder or disruptive behaviour disorder not otherwise 
specified. Its use in children with learning disabilities who have only isolated 
symptoms such as aggression, or in children who have not been assessed with the 
DSM-IV classification system for disruptive behaviour disorders is therefore 
uncertain.  
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5.2.5. Therapeutic dose 
All studies used the oral form of risperidone, while the intramuscular depot 
preparation was not used, therefore no conclusions can be drawn about the injectable 
form of the medication. Dosages ranged from 0.01 mg/kg/day to 0.09 mg/kg/day, 
although doses below 0.03mg/kg/day were not well represented overall. There was no 
direct comparison of different dosages, therefore no dose-response outcomes could be 
ascertained. The duration of risperidone treatment was short term, either 4 or 6 weeks, 
with a significant number of participants not reaching the 6 week endpoint due to high 
attrition rates. The effects of using risperidone beyond 6 weeks could also not be 
assessed.  
 
5.3. QUALITY OF THE EVIDENCE  
This study review included four studies involving 279 children with learning 
disability. The overall methodological quality of the studies was insufficient to 
provide robust evidence in this review. The studies had relatively small sample sizes, 
with two studies lacking sufficient statistical power (Buitelaar 2001; Van Bellinghen 
2001).  An overall assessment showed a moderately high risk of bias in the studies 
(see Figure 2), raising the possibility of artificially influencing the treatment effect 
estimates in the results. Attrition, in particular, was assessed as high in the two largest 
studies (Aman 2002; Snyder 2002), and even though the authors reported methods to 
account for missing data (intent-to-treat analysis), bias could still have affected the 
study outcomes. The fact that all studies were funded by Ortho-McNeil-Janssen, the 
manufacturer of the original Risperdal patented drug, raises further questions about 
the independence of the results.   
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5.4. POTENTIAL BIASES IN THE REVIEW PROCESS  
All attempts were made to minimize the introduction of bias in the review process 
itself, by extensive and rigorous screening and selection of potentially eligible studies 
from major electronic databases and the systematic and methodical assessment of the 
quality of the included studies. This thorough process did result in the finding of an 
unpublished study. However, despite all these efforts it is possible that selection bias 
could have been introduced as the databases EMBASE and LILACS were not 
available to conduct a search. The conference proceedings of the annual American 
Psychiatric Association (APA) conference were also not available to be handsearched 
as originally planned. 
 
5.5. AGREEMENTS / DISAGREEMENTS WITH OTHER STUDIES OR REVIEWS  
Cochrane systematic reviews have been published on the use of antipsychotic agents 
(including risperidone) for challenging and disruptive behaviours in adults with 
learning disability and on the use of risperidone for aggression and self injury in 
autism spectrum disorders.  This study review is in agreement with systematic and 
other literature reviews that some evidence exists to suggest that risperidone is helpful 
for the treatment of disruptive types of behaviour (such as aggression), although the 
methodological quality and inadequate statistical power of the currently available 
studies limits its widespread application.  
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6. AUTHOR’S CONCLUSIONS  
6.1. IMPLICATIONS FOR PRACTICE  
(i). The evidence for risperidone management of disruptive behaviour in children and 
adolescents with learning disability is not conclusive; there is some evidence to show 
that risperidone may improve behaviour in certain cases of disruptive behaviour in 
children with learning disability, however the current evidence is weakened by poor 
methodological quality. The known potential risk of risperidone to cause serious 
adverse effects and the unknown long term safety profile should caution clinicians in 
its use. 
 
ii). If risperidone is used in children with learning disability, it should only be used to 
treat disruptive type behaviours on a short term basis for symptomatic care as part of a 
multidisciplinary approach. It should never be used as a first line treatment for the 
management of disruptive type behaviours, and pharmacological treatment should 
always be considered second line to non-pharmacological methods of management. 
Risperidone should preferably only be prescribed by a specialist in the field. The 
patient should be followed-up on a regular basis with regular monitoring of potential 
adverse effects (especially weight gain, sedation and prolactin levels). After 
symptoms have been managed, a trial of withdrawal from the drug should be 
implemented. No child should received risperidone therapy routinely on a long term 
basis. Attempts to withdraw the medication should be carried out as a matter of 
course.  
 
(iii). The optimum duration of treatment is not yet established. 
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(iv). It is very important to exclude other causes (organic, psychological, social) of 
disruptive behaviour and due consideration should be given to the differential 
diagnoses of disruptive behaviour, before considering pharmacotherapy such as 
risperidone as a treatment option. 
 
(v). Before  risperidone is prescribed to a child with learning disability and disruptive 
behaviour both the caregiver  and patient  must be made  aware of the paucity of  
available evidence to support the efficacy and safety of its use for this purpose. It is 
essential that caregivers in the USA know that risperidone is being used  off-label as it 
is not registered or indicated for use in children with learning disability and disruptive 
behaviour. 
 
(vi). South African clinicians need to be aware of the available  evidence on the 
efficacy of risperidone as well as  the discrepancy between the South African and 
USA approval of risperidone for use in disruptive behaviours in children with learning 
disability. 
 
(vii). Risperidone should not replace other management modalities of disruptive 
behaviour as first line treatment in poorly resourced communities that have 
suboptimal facilities for managing patients with learning disability and disruptive 
behaviour. 
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6.2. IMPLICATIONS FOR RESEARCH  
(i).   Further research is needed to add to the current body of evidence.  
 
(ii). The methodological quality of future research designs should be improved to 
reflect the true effect of risperidone in this population. Adequate study sample sizes, 
the reporting of standard deviations, the publication of negative trials and trials not 
sponsored by the drug manufacturer would decrease some of the bias existing in the 
current literature and increase the statistical power for analyses.   
 
(iii). Studies need to use standardised diagnostic criteria to diagnose behavioural 
problems in children with learning disability. The ICD-10 Mental retardation 
classification should be considered as such a standard, as it contains a descriptive 
behavioural component.   
 
(iv). Studies should use the same standardised rating scales to assess disruptive 
behaviours, to enable comparison of studies. 
 
(v). Future studies need to be of longer duration to assess the long term effects and 
safety profile of risperidone, especially on growth and sexual maturation. 
 
(vi). Studies should report the levels of severity of learning disability in the 
participants in more detail. 
 
(vii). Studies need to compare risperidone to other treatment modalities viz. other 
drugs and non-pharmacological treatments. 
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(viii). Studies undertaken in locations outside the USA and Canada would enhance the 
applicability and validity of the evidence. 
 
(ix). More research is needed on the efficacy of other treatment modalities of 
disruptive behaviours in learning disabled children.  
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APPENDIX A:  CHARACTERISTICS OF STUDIES  
Table A1.  Characteristics of Included Studies  
Aman 2002 Characteristics table 
Methods 
Allocation: Randomised, stratified by diagnosis (conduct 
disorder versus other diagnoses (oppositional defiant disorder or 
disruptive behaviour disorder not otherwise specified)). No 
further details on method of randomization. 
 
Blindness: Double-blind, risperidone and placebo identical in 
appearance, taste and smell. No further details. 
 
Duration: 1 week single blind treatment with placebo to exclude 
placebo responders, remaining patients entered 6 weeks double 
blind phase. 
Participants 
Inclusion criteria: 
Children with total rating ≥24 on the conduct problem subscale 
of the Nisonger Child Behaviour Rating Form 
DSM-IV axis I diagnosis of conduct disorder, oppositional 
defiant disorder, or disruptive behaviour disorder not otherwise 
specified 
DSM-IV axis II diagnosis of subaverage IQ (IQ ≥36 and ≤84) 
Vineland Adaptive Behaviour Scale score ≤84 
Sufficiently severe symptoms that investigator determined need 
for antipsychotic treatment 
Responsible accompanying parent or caretaker for study visits, 
to provide reliable assessments, and to dispense study 
medication. 
 
Exclusion criteria: 
Previous use of risperidone 
Diagnosis of pervasive developmental disorder, schizophrenia, 
or other psychotic disorder 
Head injury as a cause of intellectual disability 
Seizure disorder requiring medication 
Known hypersensitivity to risperidone or neuroleptics 
History of tardive dyskinesia or neuroleptic malignant syndrome
Serious or progressive illness 
Human Immunodeficiency Virus (HIV) infection 
Use of an investigational drug within previous 30 days 
Laboratory values of standard blood screening outside the 
normal range (unless investigator determined that deviations not 
clinically relevant) 
Sexually active female subjects of childbearing age not using a 
medically validated birth control method 
Total study N = 118 subjects 
Recruited and screened = 142 subjects 
Randomised = 119 subjects 
 74
Age: 5 - 12 years 
Age mean in risperidone group = 8.7 years 
Age mean in placebo group = 8.1 years 
Sex: 97 male, 21 female 
Risperidone group = 47 boys, 8 girls 
Placebo group = 50 boys, 13 girls 
Location: 
Multi-centre study with 11 study sites (only USA mentioned, 
but locations of all 11 study sites not detailed) 
Participants recruited at centres for developmental disabilities 
Interventions 
1. Risperidone: N=55 
2. Placebo: N=63 
Dosage and administration: 
Commenced on day 1 at a dose of 0.01 mg/kg per day and 
increased to 0.02 mg/kg per day on day 3 
Dose adjusted at weekly intervals as necessary only until 28 
days, then dose remained constant 
Maximum dose of 0.06mg/kg per day 
Administered once daily in the morning unless subject 
experienced breakthrough symptoms in evening, then 
administered twice daily 
Risperidone and placebo identical in appearance, taste and smell
Outcomes 
Primary efficacy measures: 
1. Conduct problem subscale of Nisonger Child Behaviour 
Rating Form 
Secondary efficacy measures: 
2. Other subscales in problem behaviour section and social 
competence section of Nisonger Child Behaviour Rating Form  
3. Aberrant Behaviour Checklist subscale  
4. Clinical Global Impression (CGI) severity scale and CGI 
improvement scale  
5. Visual Analogue Scale for target symptom  
 
Other outcome measures: 
6. Adverse events 
7. Prolactin  
8. Growth Hormone 
9. Continuous Performance Test 
10. California Verbal Learning Test, Childrens' version 
11. Extrapyramidal Symptom Rating Scale  
12. Vital signs  
13. Weight 
Notes 
Concomitant use of other antipsychotics, anticonvulsants, 
antidepressants, lithium, carbamazepine, valproic acid, or 
cholinesterase inhibitors not permitted. 
Psychostimulants (e.g., methylphenidate, pemoline, 
dextroamphetamine) permitted if dose stable for 30 days. 
Behavioural therapy permitted if initiated at least 30 days before 
the start of study. 
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No medications for sleep or anxiety to be initiated during trial. 
Subjects receiving antihistamines, chloral hydrate, or melatonin 
for sleep before the screening visit could continue this 
medication unchanged during the trial. 
Medications commonly used to treat extrapyramidal symptoms 
(e.g.,diphenhydramine, benztropine, trihexyphenidyl) were 
discontinued at study entry. If extrapyramidal symptoms arose 
during study, the dose of study medication was decreased. If this 
resulted in deterioration of conduct disorder symptoms or failed 
to improve the extrapyramidal symptoms, anti-extrapyramidal 
symptom medication could be considered. 
 
 
Aman 2002 Risk of bias table  
Item Judgment Description 
Adequate 
sequence 
generation? 
Unclear 
"randomized" "were randomly assigned to treatment 
groups" "randomization was stratified according by 
diagnosis". Insufficient information to determine. 
Allocation 
concealment? Unclear No information. 
Blinding? Yes "double-blind" "two study solutions were identical in appearance, taste and smell" 
Incomplete 
outcome data 
addressed? 
No 
Attrition rates and reasons reported  
Intention-to-treat-analysis done 
Overall attrition 26 % 
Unbalanced in numbers across risperidone and placebo 
group (Risperidone 12/55 (21 %), Placebo 19/63 (30 %) 
Unbalanced in reason for attrition across risperidone and 
placebo group 
Risperidone 4 (7.3%) insufficient response 
                    3 (5.5%) non-compliance 
                    2 (3.6%) adverse events 
                    1 (1.8%) LTFU 
                    1 (1.8%) consent withdrawn 
                    1 (1.8%) medication lost 
The three risperidone participants on whom no outcome 
data was collected and then excluded from efficacy 
analysis do not seem to be included in the study’s 
attrition report. The total risperidone attrition could thus 
be 15/55 (27%) 
Placebo 15 (23.8%) insufficient response 
               3 (4.8%) LTFU 
               1 (1.6%) consent withdrawn 
Free of selective 
reporting? Yes All outcomes and standard deviations reported. 
Free of other 
bias? Unclear Manufacturer sponsored. 
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Buitelaar 2001 Characteristics table 
Methods 
Allocation: Randomised, randomization code was generated by 
computer in blocks of 4 numbers.  
 
Blindness: Double-blind, psychiatrist outcome assessors blinded 
to treatment. 
 
Duration: 2 week baseline period, 6 weeks double-blind 
treatment period, and then a 2 week washout period. 
Participants 
Inclusion criteria: 
Children aged between 12 and 18 years of age 
Full scale IQ between 60 and 90 on the Wechsler Intelligence 
Scale for Children, Revised 
DSM-IV axis I diagnosis of conduct disorder, oppositional 
defiant disorder, or attention-deficit/hyperactivity 
Aggressive behaviour persisted in ward (at least score of 1 on 
Overt Aggression Scale (OAS-M)) 
Clinical indication for drug treatment 
Aggressive behaviour failed to respond to behaviour treatment 
approach 
 
Exclusion criteria: 
Neurologic, pulmonary, cardiac or hepatic disease 
Diagnosis of primary mood disorder, schizophrenia, or other 
active psychosis, or suicidality 
Comorbid DSM IV diagnosis of substance abuse disorder 
Major change in treatment regime anticipated in near future 
Female subjects, who were pregnant or using inadequate 
contraception 
Considered inappropriate to discontinue current psychotropic 
medication 
 
Total study N = 38 subjects 
Recruited and screened = 145 subjects 
Eligible and invited to partake in study = 45 
Randomised = 38 subjects 
Age: 12-18 years 
Age mean in risperidone group = 14 years 
Age mean in placebo group = 13.7 years 
Sex: 33 male, 5 female 
Risperidone group = 17 boys, 2 girls 
Placebo group = 16 boys, 3 girls 
Location: 
Tertiary referral centres in the Beele (Voorts) and Groot Emaus 
(Ermelo), in the Netherlands, for adolescents with severe 
aggressive behaviour and borderline intelligence or mild 
learning disability. 
Interventions 1. Risperidone: N = 19 2. Placebo: N =19 
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Dosage and administration: 
Commenced on day 1 at a dose of 1mg per day 
6 week double blind phase consisted of 2 week dose-rising 
phase and 4 week fixed-dose phase 
Titration started with 0.5 mg twice daily (8 am and 6 pm) 
Maximum dose of 5 mg twice per day 
Outcomes 
Primary efficacy measures: 
1. Clinical Global Impression (CGI) severity scale 
 
Secondary efficacy measures: 
2. Overt Aggrion Scale (OAS-M) 
3. Aberrant Behaviour Checklist subscale 
 
Other outcome measures: 
4. Extrapyramidal Symptom Rating Scale (ESRS) 
5. Vital signs 
6. Weight 
7. Adverse events 
Notes 
No concomitant psychotropic medication allowed during double 
blind period, except for biperiden and oxazepam for 
extrapyramidal symptoms and sedation. 
 
Buitelaar 2001 Risk of bias table  
Item Judgment Description 
Adequate sequence 
generation? Yes 
"randomization code had been generated by computer 
in blocks of 4 numbers" 
Allocation 
concealment? Unclear No information on allocation concealment. 
Blinding? Yes 
"double-blind conditions" "dosage was 
adjusted....responsible psychiatrist (JKB or RJ vd G) 
who was blind to the treatment" 
Incomplete outcome 
data addressed? Yes 
Attrition adequately reported and described 
Attrition: Placebo 2  
                Risperidone 1 (during washout period) 
Endpoint analysis, last observation carried forward 
Free of selective 
reporting? Yes All outcomes reported.  
Free of other bias? Unclear Manufacturer sponsored. 
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Snyder 2002 Characteristics table 
Methods 
Allocation: Randomized, placebo-controlled parallel-group. 
Stratified by diagnosis (conduct disorder vs oppositional defiant 
disorder or disruptive behaviour disorder not otherwise 
specified). No further details on method of randomization. 
 
Blindness: Double-blind. No further details. 
 
Duration: 1 week single blind treatment with placebo to exclude 
placebo responders, remaining patients entered 6 weeks double 
blind phase. 
Participants 
Inclusion criteria: 
DSM-IV diagnosis of CD, ODD, or DBD-NOS 
Parent/caregiver rating of <24 or higher on the Conduct Problem 
subscale of the Nisonger Child Behaviour Rating Form 
IQ between 36 and 84 inclusive 
Vineland Adaptive Behaviour Scale score <84 
Healthy on the basis of a pre-trial physical examination, medical 
history, and ECG 
Consent by parent/caregiver 
 
Exclusion criteria: 
Diagnosis of pervasive developmental disorder, schizophrenia, 
or other psychotic disorders 
Head injury as a cause of impaired IQ 
Seizure condition requiring medication 
Females who were sexually active without a reliable form of 
birth control 
Serious or progressive illness or clinically abnormal laboratory 
values 
History of tardive dyskinesia, neuroleptic malignant syndrome, 
or hypersensitivity to any antipsychotic drug 
Known presence of Human Immunodeficiency Virus (HIV) 
Previous treatment with risperidone 
 
Total study N = 110 subjects 
Recruited and screened = 133 subjects 
Placebo responders excluded: 23 subjects  (17.3%) 
Randomised to treatment/control = 110 subjects 
Did not complete full 6 week study = 25 subjects (22.7%) 
Age: 5 - 12 years 
Age mean in risperidone group = 8.6 years 
Age mean in placebo group = 8.8 years 
Sex: 83 male, 27 female 
Risperidone group = 41 boys, 12 girls 
Placebo group = 42 boys, 15 girls 
Location: 
Multi-centre study with 16 clinical sites (10 in Canada, 4 in the 
United States, and 2 in South Africa) 
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Participants were recruited from clinical practices of the 
investigators and colleagues, local school districts, self-referrals 
via newsletter stories, and newspaper and radio advertising 
Interventions 
1.Risperidone: N=53 
2.Placebo: N=57 
Dosage and administration: 
Medication (risperidone or placebo) was given as an oral 
solution in the morning 
Dose began at 0.01 mg/kg for the first 2 days and at 0.02 mg/kg 
for the next 5 days 
The physician could increase the dosage weekly by 0.02 mg/kg 
per day to a maximum of 0.06 mg/kg per day, or decrease the 
dose by any amount for the remainder of the trial 
Outcomes 
Primary efficacy measures: 
1.Conduct problem subscale of Nisonger Child Behaviour
Rating Form 
2.Other subscales in problem behaviour section and social 
competence section of Nisonger Child Behaviour Rating Form 
 
Secondary efficacy measures: 
3.Aberrant Behaviour Checklist subscale 
4.Behaviour Problems Inventory 
5.Visual Analogue Scale for target symptom 
6.Clinical Global Impression (CGI) severity scale and CGI 
improvement scale 
 
Other outcome measures: 
7.Reported adverse events 
8.Extrapyramidal Symptom Rating Scale 
9.Prolactin 
10.Vital signs 
11.Weight 
12.Cognitive tests (Continuous Performance Test and modified 
children’s' version of California Verbal Learning Test) 
Notes 
Subjects taking previously prescribed stable dosages of 
concomitant medication for 30 days prior to trial entry were 
included provided the concomitant medication was expected to 
remain stable for the duration of the trial.  
Examples of allowed concomitant medications included 
medication for pre-existing medical conditions, 
psychostimulants (for co-morbid attention-deficit/hyperactivity 
disorder [ADHD]), and sleep medication (antihistamines, 
chloral hydrate, and melatonin).  
No other medication was allowed with the exception of 
anticholinergic medication to treat EPS, if it occurred during the 
trial. 
 
 80
Snyder 2002 Risk of bias table  
Item Judgment Description 
Adequate sequence 
generation? Unclear 
"randomized" "stratified by diagnosis (conduct 
disorder versus oppositional defiant disorder or 
disruptive behaviour disorder not otherwise specified)"
"Janssen Research Foundation prepared the 
randomization list, and subjects were assigned a 
medication kit upon randomization" 
Allocation 
concealment? Unclear No information on allocation concealment 
Blinding? Unclear "double-blind" 
Incomplete outcome 
data addressed? No 
Attrition rates and reasons reported  
Intention-to-treat-analysis done 
Overall attrition 22.7% 
Unbalanced in numbers across risperidone and placebo 
group (Risperidone 6/53 (11.3%), Placebo 19/57 
(33.3%) 
Unbalanced in reason for attrition across risperidone 
and placebo group 
Risperidone 2  (3.8%) insufficient response 
                    1  (1.9%) LTFU 
                    3  (5.7%) loss of consent 
Placebo      19 (33.3%) insufficient response 
Free of selective 
reporting? Yes All outcomes reported. 
Free of other bias? Unclear Manufacturer sponsored. 
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Van Bellinghen 2001 Characteristics table 
Methods 
Allocation: Randomised, No details on method of 
randomization. 
 
Blindness: Double-blind, No further details. 
 
Duration: 4 weeks double blind period 
Participants 
Inclusion criteria: 
Children between the ages of 6 and 18 years 
IQ between 45 and 85 
Persistent behavioural disturbances ( hostility, aggressiveness, 
irritability, agitation or hyperactivity) 
 
Exclusion criteria: 
Diagnosis of clinical relevant non-neurologic disease 
Laboratory values of standard blood screening outside the 
normal range 
Epileptic crisis in the previous 3 months 
Remoxipride treatment in the previous 4 weeks 
Oral neuroleptics or psychotropics in the previous week 
Previous Remoxipride treatment with abnormal haematological 
values 
Depot neuroleptic injection within one treatment cycle of the 
time of selection 
Use of an investigational drug within previous 4 weeks 
Female subjects of childbearing age not using a medically 
validated birth control method, or pregnant or lactating 
 
Total study N = 13 subjects 
Age: 6 - 14 years 
Age mean in risperidone group = 10.5 years 
Age mean in placebo group = 11 years 
Sex: 5 male, 8 female 
Risperidone group = 2 boys, 4 girls 
Placebo group = 3 boys, 4 girls 
Location: 
Institutionalised, Belgium 
Interventions 
1. Risperidone: N = 6 
2. Placebo: N = 7 
Dosage and administration: 
Dose once daily in the evenings 
During the first week dose was titrated from 0.01 to 0.04 
mg/kg/day 
Followed by 3 week flexible dosing period 
From day 7, dose increase to 0.05 mg/kg/day if the CGI score 
remained unchanged or worsened 
From day 14, dose increased by 0.02 mg/kg/week if the CGI 
score worsened 
Maximum dose of 0.09 mg/kg/day 
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Outcomes 
Efficacy measures: 
1. Clinical Global Impression (CGI) severity scale 
2. Personal Assessment Checklist (PAC) 
3. Aberrant Behaviour Checklist  
4. Extrapyramidal Symptom Rating Scale (ESRS) 
5. Visual Analogue Scale 
6. Vital signs 
7. Weight 
Notes 
Nil lost to follow up 
Mean IQ 75.6 
Anti – epileptic treatment permitted in 1 patient (Sodium 
Valproate) and Ritalin in 1 patient. 
 
 
Van Bellinghen 2001 Risk of bias table  
Item Judgment Description 
Adequate sequence generation? Unclear "patients were randomized to " 
Allocation concealment? Unclear No information on allocation concealment. 
Blinding? Unclear "double-blind" 
Incomplete outcome data 
addressed? Yes 
"all patients completed the study"  
Intent-to-treat analysis 
Free of selective reporting? Unclear No standard deviations reported with data. 
Free of other bias? Unclear Manufacturer sponsored. 
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Table A2.  Characteristics of Excluded Studies  
Ad-Dab'bagh 2000  
Reason for exclusion Retrospective chart review 
Biederman 2006  
Reason for exclusion Discussion of Aman 2002 data 
Brylewski 2004  
Reason for exclusion Cochrane systematic review on adults 
Buitelaar 2000  
Reason for exclusion Open label trial, mixed diagnoses 
Croonenberghs 2005  
Reason for exclusion Open label trial 
Findling 2000  
Reason for exclusion Randomised Controlled Trial (RCT), children with conduct disorder, no learning disability 
Findling 2004  
Reason for exclusion Open label extension trial 
Friedlander 2001  
Reason for exclusion Chart review 
Gagiano 2005  
Reason for exclusion RCT, adults 
Haas 2008  
Reason for exclusion Open label extension trial, no learning disability 
Hellings 2006  
Reason for exclusion Cross-over design, children and adults 
La Malfa 2006  
Reason for exclusion Literature review 
LeBlanc 2005  
Reason for exclusion Discussion of Aman 2002 and Snyder 2002 data 
Matson 2000  
Reason for exclusion Literature review 
Pandina 2006  
Reason for exclusion Literature review 
Pandina 2007  
Reason for exclusion Not RCT, pooled data from Aman 2002; Croonenberghs 2005; Findling 2004;Snyder 2002; Turgay 2002 
Read 2008  
Reason for exclusion Open label, no control group 
Reyes 2006  
Reason for exclusion Open label extension 
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Reyes 2006a  
Reason for exclusion Open label extension 
Reyes 2006b  
Reason for exclusion RCT, range of intellect 
Turgay 2002  
Reason for exclusion Open label extension trial 
Tyrer 2008  
Reason for exclusion RCT in adults, Risperidone and Haloperidol 
Valdovinos 2002  
Reason for exclusion Case studies, adults 
Valdovinos 2004  
Reason for exclusion Cross-over design, adults and children 
Vanden 1993  
Reason for exclusion Cross-over design, children and adults 
Zarcone 2001  
Reason for exclusion Cross-over design, children and adults 
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APPENDIX B:  DATA AND ANALYSES  
 
Table B1.  Nisonger Child Behaviour Rating Scale 
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
1. Compliant/ calm 2 225 Mean Difference (IV, Fixed, 95% CI) 1.89 [0.94, 2.84] 
2. Adaptive/ social 2 225 Mean Difference (IV, Fixed, 95% CI) 1.54 [0.88, 2.20] 
3. Conduct problems 2 225 Mean Difference (IV, Fixed, 95% CI) -8.67 [-11.72, -5.62]
4. Insecure/ anxious 2 225 Mean Difference (IV, Fixed, 95% CI) -4.24 [-6.13, -2.35] 
5. Hyperactive 2 225 Mean Difference (IV, Fixed, 95% CI) -2.84 [-4.39, -1.30] 
6. Self-injury/ 
stereotypic 2 225 
Mean Difference 
(IV, Fixed, 95% CI) -0.83 [-1.71, 0.05] 
7. Self-isolated/ 
ritualistic 2 225 
Mean Difference 
(IV, Fixed, 95% CI) -1.47 [-2.45, -0.48] 
8. Overly sensitive 2 225 Mean Difference (IV, Fixed, 95% CI) -0.95 [-1.87, -0.04] 
 
 
Table B2.  ABC (Aberrant Behaviour Checklist)  
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
1. Irritability 3 263                 Mean Difference  (IV, Fixed, 95% CI) -4.00 [-6.07, -1.92] 
2. Social withdrawal/ 
lethargy 3 263 
Mean Difference  
(IV, Fixed, 95% CI) -2.55 [-4.07, -1.03] 
3. Hyperactivity 3 263 Mean Difference  (IV, Fixed, 95% CI) -0.77 [-1.68, 0.13] 
4. Stereotypy 3 263 Mean Difference  (IV, Fixed, 95% CI) -6.65 [-9.24, -4.05] 
5. Inappropriate 
speech 3 263 
Mean Difference  
(IV, Fixed, 95% CI) 0.77 [0.15, 1.40] 
 
 
Table B3.  CGI-I (Clinical Global Impression - Global Improvement) (RR)  
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
Participants improved 
/ very much improved 2 225 
Risk Ratio (M-H, 
Fixed, 95% CI) 2.69 [2.00, 3.62] 
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Table B4.  BPI (Behaviour Problems Inventory Subscale)  
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
1. Aggressive / 
destructive 2 225 
Mean Difference  
(IV, Fixed, 95% CI) -4.96 [-7.31, -2.61] 
2. Self-injurious 2 225 Mean Difference  (IV, Fixed, 95% CI) -0.41 [-2.12, 1.29] 
3. Stereotyped 2 225 Mean Difference  (IV, Fixed, 95% CI) -0.38 [-1.46, 0.69] 
 
 
Table B5.  VAS (Visual Analogue Scale) [mm] 
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
Severity of most 
troublesome symptom 2 225 
Mean Difference  
(IV, Fixed, 95% CI) 
-22.56  
[-24.09, -21.02] 
 
 
Table B6.  ESRS (Extrapyramidal Symptom Rating Scale for Children)  
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
Parkinsonism 2 151 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.72, 0.60] 
 
 
Table B7.  Weight  [kg] 
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
Weight 4 276 Mean Difference (IV, Fixed, 95% CI) 1.46 [0.96, 1.97] 
 
 
Table B8.  Sedation / somnolence (RR) 
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
Sedation / somnolence 3 266 Risk Ratio (M-H, Fixed, 95% CI) 4.00 [2.37, 6.76] 
 
 
Table B9.  Prolactin  [ng/mL] 
Outcome or 
Subgroup Studies Participants Statistical Method Effect Estimate 
1. Female Prolactin    
    levels 2 38 
Mean Difference 
(IV, Fixed, 95% CI) 14.56 [7.35, 21.76] 
2. Male Prolactin  
    levels 2 125 
Mean Difference 
(IV, Fixed, 95% CI) 20.70 [15.73, 25.68]
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APPENDIX C:  FIGURES  
 
C1  Nisonger Child Behaviour Rating Scale 
 
Figure C1.1  Compliant / calm 
 
 
 
Figure C1.2  Adaptive / social 
 
 
 
Figure C1.3  Conduct problems 
 
 
 
Figure C1.4  Insecure / anxious 
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Figure C1.5  Hyperactive 
 
 
Figure C1.6  Self-injury / stereotypic 
 
 
Figure C1.7 Self-isolated / ritualistic 
 
 
Figure C1.8  Overly sensitive 
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C2  ABC (Aberrant Behaviour Checklist) 
Figure C2.1  Irritability 
 
 
Figure C2.2  Social withdrawal / lethargy 
 
 
Figure C2.3  Hyperactivity 
 
 
Figure C2.4  Stereotypy 
 
 
Figure C2.5  Inappropriate speech 
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C3  CGI-I (Clinical Global Impression - Global Improvement) (RR) 
Figure C3.1  CGI-I  Participants improved/ very much improved 
 
 
 
C4  BPI (Behavior Problems Inventory Subscale)  
Figure C4.1  Aggressive/ destructive 
 
 
Figure C4.2  Self-injurious 
 
 
Figure C4.3  Stereotyped 
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C5  VAS (Visual Analogue Scale) [mm] 
Figure C5.1  Severity of most troublesome symptom [mm] 
 
 
 
C6  ESRS (Extrapyramidal Symptom Rating Scale for Children) 
Figure C6.1  Parkinsonism 
 
 
 
C7  Weight [kg] 
Figure C7.1  Weight [kg] 
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C8  Sedation / somnolence 
Figure C8.1  Sedation / somnolence 
 
 
C9  Prolactin [ng/mL] 
Figure C9.1  Female Prolactin levels [ng/mL] 
 
 
 
Figure C9.2  Male Prolactin levels [ng/mL] 
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APPENDIX D: ETHICS CLEARANCE CERTIFICATE 
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APPENDIX E:  ELIGIBILITY FORM 
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APPENDIX F:  DATA COLLECTION FORM 
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APPENDIX G:  AUTHOR DATA REQUEST FORM 
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